

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2015/168555 A1

(43) International Publication Date
5 November 2015 (05.11.2015)

WIPO | PCT

(51) International Patent Classification:

A61K 31/5517 (2006.01)

(21) International Application Number:

PCT/US2015/028798

(22) International Filing Date:

1 May 2015 (01.05.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/987,813	2 May 2014 (02.05.2014)	US
61/990,459	8 May 2014 (08.05.2014)	US
61/990,469	8 May 2014 (08.05.2014)	US

(71) Applicant: ONCOETHIX SA [CH/CH]; Avenue de l'Eysee 32, CH-1006 Lausanne (CH).

(72) Inventor; and

(71) Applicant : NOEL, Kay [US/US]; 8371 Terrace Drive, El Cerrito, CA 94530 (US).

(74) Agents: LEACH, Justine, M. et al.; Morgan Lewis & Bockius LLP, 1701 Market Street, Philadelphia, PA 19103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHOD OF TREATING RESISTANT NON-HODGKIN LYMPHOMA, MEDULLOBLASTOMA, AND/OR ALK+NON-SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS

25% FORMULA (1-1)/EUDRAGIT L100-55 SOLID DISPERSION




FIG. 1A

(57) Abstract: A method of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer in a mammal by administering a solid dispersion comprising an amorphous thienotriazolo diazepine compound of the Formula (1) wherein R' is alkyl having a carbon number of 1-4, R2 is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, R3 is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; -NR 5 -(CH 2)m-,R6 wherein R5 is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and R6 is phenyl or pyridyl optionally substituted by a halogen atom.

WO 2015/168555 A1

TITLE OF THE INVENTION

METHOD OF TREATING RESISTANT NON-HODGKIN LYMPHOMA,
MEDULLOBLASTOMA, AND/OR ALK+ NON-SMALL CELL LUNG CANCER USING
THIENOTRIAZOLODIAZEPINE COMPOUNDS

5

FIELD OF INVENTION

[0001] The present disclosure describes methods of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer using thienotriazolodiazepine compounds that have improved solubility and bioavailability and may be provided in the form of solid dispersions.

10

BACKGROUND OF THE INVENTION

[0002] The compound of Formula (1), described herein below, has been shown to inhibit the binding of acetylated histone H4 to the tandem bromodomain (BRD)-containing family of transcriptional regulators known as the BET (bromodomains and extraterminal) proteins, which include BRD2, BRD3, and BRD4. *See* U.S. Patent Application Publication No. 2010/0286127 A1, which is incorporated herein by reference in its entirety. The BET proteins have emerged as major epigenetic regulators of proliferation and differentiation and also have been associated with predisposition to dyslipidemia or improper regulation of adipogenesis, elevated inflammatory profile and risk for cardiovascular disease and type 2 diabetes, and increased susceptibility to autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus as reported by Denis, G.V. “Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation,” *Discov Med* 2010; 10:489-499, which is incorporated herein by reference in its entirety. Accordingly, the compound of formula (II) may be useful for treatment of various cancers, cardiovascular disease, type 2 diabetes, and autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus.

25

BRIEF SUMMARY OF THE INVENTION

[0003] In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer using the compositions described herein.

[0004] In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer in a mammal

comprising: administering to a patient in need a pharmaceutically acceptable amount of a composition comprising a solid dispersion according to any of the compositions described in Sections III, IV, V and VI described herein.

[0005] In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma in a mammal wherein the resistant non-Hodgkin lymphoma can be a B-cell non-Hodgkin lymphoma or a T-cell non-Hodgkin lymphoma. In some embodiments the B-cell non-Hodgkin lymphoma can be a Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma. In some embodiments the T-cell resistant non-Hodgkin lymphoma can be selected from the list consisting of mycosis fungoides, anaplastic large cell lymphomas, and precursor T-lymphoblastic lymphoma. In some embodiments the resistant non-Hodgkin lymphoma can be diffuse large B-cell lymphoma or mantle cell lymphoma.

[0006] In some embodiments the medulloblastoma can be classic medulloblastoma, desmoplastic nodular medulloblastomas, large-cell medulloblastomas, medulloblastomas with neuroblastic or neuronal differentiation, medulloblastomas with glial differentiation, medulloblastomas, or melanotic medulloblastomas. In some embodiments the medulloblastoma can be Wnt medulloblastoma, Shh medulloblastoma, Group 3 medulloblastoma or Group 4 medulloblastoma. In some embodiments Wnt medulloblastoma is Wnt α medulloblastoma or Wnt β medulloblastoma. In some embodiments Shh medulloblastoma can be Shh α medulloblastoma, Shh β medulloblastoma, or Shh γ medulloblastoma.

[0007] In some embodiments the ALK + non-small cell lung cancer is characterized by tumor cells having greater than about 15% ALK positivity. In some embodiments the ALK + non-small cell lung cancer is characterized by tumor cells having greater than about 10% ALK positivity. In some embodiments the ALK + non-small cell lung cancer comprises tumor cells having an EML4 gene fused to an ALK gene. In other embodiments the ALK + non-small cell lung cancer comprises tumor cells having an KIF5B gene, TFG gene, or KLC1 gene fused to an ALK gene.

[0008] In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma in a mammal comprising the step of administering a pharmaceutically acceptable amount of a composition to a patient wherein the composition comprises: (1) any of the thienotriazolodiazepine compositions described in Sections III, IV, or V herein; and (2) an mTOR inhibitor, a BTK inhibitor, an HDAC inhibitor, an anti-CD20 monoclonal antibody, DNA methyltransferase inhibitor and an immunomodulator, or a combination thereof. The thienotriazolodiazepine composition and the mTOR inhibitor (or BTK inhibitor, HDAC inhibitor, anti-CD20 monoclonal antibody, DNA methyltransferase inhibitor, or immunomodulator) can be

administered either simultaneously or sequentially. In some embodiments the combination can produce a synergistic effect.

[0009] In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma in a mammal wherein the BTK inhibitor can be selected from the group consisting of: 5 ibrutinib, GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292, ON0-4059, CNX- 774, LFM-A13, telTeic acid, QL47, and esters, derivatives, prodrugs, salts, and complexes thereof.

[0010] In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma in a mammal wherein the mTOR inhibitor can be selected from the group consisting of: BEZ235, everolimus, rapamycin, AZD8055, PI-103, temisirolimus, Ku-0063794, GDC-0349, torin 2, INK 10 128, AZD2014, NVP-BGT226, PF-04691502, CH5132799, GDC-0980, torin 1, WAY-600, WYE-125132, WYE-687, GSK2126458, PF-05212384, PP-121, OSI-027, palomid 529, PP242, XL765, GSK1059615, WYE-354, deforolimus, and esters, derivatives, 15 prodrugs, salts, and complexes thereof.


[0011] In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma in a mammal wherein the HDAC inhibitor can be selected from the group consisting of: 15 vorinostat, entinostat, pabinostat, trichostatin A, mocetinostat, belinostat, MC1568, LAQ824, ITF2357, tubastatin A HCl, CUDC-101, pracinostat, droxinostat, quisinostat, PCI-24781, 20 romidepsin, AR-42, valproic acid sodium salt, PCI-34051, tacedinaline, M344, PI3K/HDAC inhibitor I, rocilinostat, apicidin, scriptaid, tubastatin A, sodium phenylbutyrate, resminostat, and esters, derivatives, prodrugs, salts, and complexes thereof.

[0012] In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma in a mammal wherein the DNA methyltransferase inhibitor is decitabine. In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma in a mammal wherein the immunomodulator is lenalidomide.

[0013] In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma in a mammal wherein the combination composition is formed as a solid dispersion.

[0014] In some embodiments of methods of treating non-Hodgkin lymphoma in a mammal, the non-Hodgkin lymphoma is a resistant non-Hodgkin lymphoma.


[0015] In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer using 30 thienotriazolodiazepine compound of the Formula (1)



[0016] wherein

R¹ is alkyl having a carbon number of 1-4, R² is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, R³ is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; —NR⁵—(CH₂)_m—R⁶ wherein R⁵ is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and R⁶ is phenyl or pyridyl optionally substituted by a halogen atom; or —NR⁷—CO—(CH₂)_n—R⁸ wherein R⁷ is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and R⁸ is phenyl or pyridyl optionally substituted by a halogen atom, and R⁴ is —(CH₂)_a—CO—NH—R⁹ wherein a is an integer of 1-4, and R⁹ is alkyl having a carbon number of 1-4; hydroxyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group or —(CH₂)_b—COOR¹⁰ wherein b is an integer of 1-4, and R¹⁰ is alkyl having a carbon number of 1-4, including any salts, isomers, enantiomers, racemates, hydrates, solvates, metabolites, and polymorphs thereof.

[0017] In some embodiments, Formula (1) is selected from Formula (1A):



[0018]

wherein X is a halogen, R¹ is C₁-C₄ alkyl, R² is C₁-C₄ alkyl, a is an integer of 1-4, R³ is C₁-C₄ alkyl, C₁-C₄ hydroxyalkyl, C₁-C₄ alkoxy, phenyl optionally having substituent(s), or heteroaryl optionally having substituent(s), a pharmaceutically acceptable salt thereof or a hydrate thereof; and a pharmaceutically acceptable polymer. In one such embodiment, the thienotriazolodiazepine compound is formulated as a solid dispersion comprising an amorphous thienotriazolodiazepine compound.

[0019] In one embodiment, Formula (1A) is selected from the group consisting of: (i) (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo-[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof, (ii) methyl (S)-{4-(3'-cyanobiphenyl-4-yl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl}acetate, (iii) methyl (S)-{2,3,9-trimethyl-4-(4-phenylaminophenyl)-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl}acetate; and (iv) methyl (S)-{2,3,9-trimethyl-4-[4-(3-phenylpropionylamino)phenyl]-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl}acetate. In one such embodiment, Formula (1A) is (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide.

[0020] In some embodiments, the pharmaceutically acceptable polymer is hydroxypropylmethylcellulose acetate succinate. In some such embodiments, the solid dispersion has a thienotriazolodiazepine compound to hydroxypropylmethylcellulose acetate succinate (HPMCAS), weight ratio of 1:3 to 1:1. In some such embodiments, the solid dispersion exhibits a single glass transition temperature (Tg) inflection point ranging from about 130 °C to about 140 °C. In some such embodiments, a concentration of the thienotriazolodiazepine compound after exposure to the relative humidity of 75 % at 40 °C for at least one month is at least 90 % of the concentration the amorphous thienotriazolodiazepine compound prior to such exposure.

[0021] In other embodiments, the pharmaceutically acceptable polymer is PVP. In some such embodiments, the solid dispersion has a thienotriazolodiazepine compound to PVP weight ratio of 1:3 to 1:1. In some such embodiments, the solid dispersion exhibits a single glass transition temperature (Tg) inflection point ranging from about 175 °C to about 185 °C. In some such embodiments, a concentration of the thienotriazolodiazepine compound after exposure to the relative humidity of 75 % at 40 °C for at least one month is at least 90 % of the concentration the amorphous thienotriazolodiazepine compound prior to such exposure.

[0022] In another embodiment, the solid dispersion is obtained by spray drying.

[0023] In another embodiment, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1A).

[0024] In yet another embodiment, the solid dispersion provides an area under the curve (AUC) 5 value that is at least 0.5 times that of a corresponding AUC value provided by a control composition administered intravenously, wherein the control composition comprises an equivalent quantity of a crystalline thienotriazolodiazepine compound of Formula (1A).

[0025] In still yet another embodiment, the solid dispersion provides a concentration, of the amorphous thienotriazolodiazepine compound, in an aqueous in vitro test medium at pH between 10 5.0 to 7.0, of at least 5-fold greater than a concentration of a crystalline thienotriazolodiazepine compound of Formula (1A) without polymer, in a control in vitro test medium at pH between 5.0 to 7.0 test medium.

[0026] In yet another embodiment, a concentration of the amorphous thienotriazolodiazepine compound, from the solid dispersion, in an aqueous in vitro test medium having a pH of 1.0 to 2.0, 15 is at least 50% higher than a concentration of a crystalline thienotriazolodiazepine compound of Formula (1A) without polymer in an in vitro test medium having a pH between 5.0 and 7.0.

[0027] In one embodiment, the concentration of the amorphous thienotriazolodiazepine compound, is at least 50% higher compared to a concentration of thienotriazolodiazepine compound of Formula (1A), from a solid dispersion of thienotriazolodiazepine compound of the Formula (1A) 20 and a pharmaceutically acceptable polymer selected from the group consisting of: hypromellose phthalate and ethyl acrylate-methyl methacrylate-trimethylammonioethyl methacrylate chloride copolymer, wherein each solid dispersion was placed in an aqueous in vitro test medium having a pH of 1.0 to 2.0.

[0028] In one embodiment, the concentration of the amorphous thienotriazolodiazepine compound 25 of Formula (1A), is at least 50% higher compared to a concentration of thienotriazolodiazepine compound of Formula (1A), from a solid dispersion of thienotriazolodiazepine compound of the Formula (1A) and a pharmaceutically acceptable polymer selected from the group consisting of: hypromellose phthalate and ethyl acrylate-methyl methacrylate-trimethylammonioethyl methacrylate chloride copolymer, wherein each solid dispersion was placed in an aqueous in vitro 30 test medium having a pH of 1.0 to 2.0.

[0029] The present disclosure further provides for a pharmaceutical formulation, used to treat resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer, comprising a spray dried solid dispersion, as described herein, and one or more pharmaceutically

acceptable excipients selected from the group consisting of: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; colloidal silicon dioxide; magnesium stearate; and combinations thereof. In some embodiments, the pharmaceutical formulation has a bulk density ranging from 0.55 g/cc to 0.60 g/cc. In some embodiments, the pharmaceutical formation may be a 5 pharmaceutical capsule. In some embodiments, the pharmaceutical formation may be a pharmaceutical tablet.

[0030] The present disclosure further provides for a pharmaceutical formulation, used to treat resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer, comprising 10-15 wt. % of a spray dried solid dispersion, as described herein, and 10 hydroxypropylmethylcellulose acetate succinate (HPMCAS), wherein the thienotriazolodiazepine compound is amorphous in the dispersion and has a thienotriazolodiazepine compound to hydroxypropylmethylcellulose acetate succinate (HPMCAS), weight ratio of 1:3 to 1:1; 45 -50 wt. % of lactose monohydrate; 35-40 wt. % of microcrystalline cellulose; 4-6 wt. % of croscarmellose sodium; 0.8-1.5 wt. % of colloidal silicon dioxide; and 0.8-1.5 wt. % of magnesium stearate. 15 The present disclosure further provides for a method of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer, comprising administering a compound according to Formula (1) and an alkylating agent. In some embodiments the compound according to Formula I and the alkylating agent are administered sequentially, while in other embodiments the compound according to Formula (1) and the alkylating agent are administered concomitantly. In 20 some embodiments the alkylating agent comprises temozolomide.

BRIEF DESCRIPTION OF THE DRAWINGS

[0031] The foregoing summary, as well as the following detailed description of embodiments of the pharmaceutical compositions including thienotriazolodiazepine formulations and methods of the 25 present invention, will be better understood when read in conjunction with the appended drawings of exemplary embodiments. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities shown.

[0032] In the drawings:

[0033] Figure 1A illustrates dissolution profile of a comparator formulation comprising a solid 30 dispersion comprising 25% compound (1-1) and Eudragit L100-55;

[0034] Figure 1B illustrates dissolution profile of a comparator formulation comprising a solid dispersion comprising 50% compound (1-1) and Eudragit L100-55;

[0035] Figure 1C illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 25% compound (1-1) and polyvinylpyrrolidone (PVP);

5 [0036] Figure 1D illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 50% compound (1-1) and PVP;

[0037] Figure 1E illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 25% compound (1-1) and PVP-vinyl acetate (PVP-VA);

10 [0038] Figure 1F illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 50% compound (1-1) and PVP-VA;

[0039] Figure 1G illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 25% compound (1-1) and hypromellose acetate succinate (HPMCAS-M);

[0040] Figure 1H illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 50% compound (1-1) and HPMCAS-M;

15 [0041] Figure 1I illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 25% compound (1-1) and hypromellose phthalate (HPMCP-HP55);

[0042] Figure 1J illustrates dissolution profile of an exemplary formulation comprising a solid dispersion comprising 50% compound (1-1) and HMP-HP55;

[0043] Figure 2A illustrates results of *in vivo* screening of an exemplary formulation comprising a solid dispersion of 25% compound (1-1) and PVP;

20 [0044] Figure 2B illustrates results of an *in vivo* screening of an exemplary formulation comprising a solid dispersion of 25% compound (1-1) and HPMCAS-M;

[0045] Figure 2C illustrates results of an *in vivo* screening of an exemplary formulation comprising a solid dispersion of 50% compound (1-1) and HPMCAS-M;

25 [0046] Figure 3 illustrates powder X-ray diffraction profiles of solid dispersions of compound (1-1);

[0047] Figure 4A illustrates modified differential scanning calorimetry trace for a solid dispersion of 25% compound (1-1) and PVP equilibrated under ambient conditions;

[0048] Figure 4B illustrates modified differential scanning calorimetry trace for a solid dispersion of 25% compound (1-1) and HPMCAS-M equilibrated under ambient conditions;

30 [0049] Figure 4C illustrates modified differential scanning calorimetry trace for a solid dispersion of 50% compound (1-1) and HPMCAS-M equilibrated under ambient conditions;

[0050] Figure 5 illustrates plot of glass transition temperature (Tg) versus relative humidity (RH) for solid dispersions of 25% compound (1-1) and PVP or HMPCAS-M and 50% compound (1-1) and HPMCAS-MG;

5 [0051] Figure 6 illustrates modified differential scanning calorimetry trace for a solid dispersion of 25% compound (1-1) and PVP equilibrated under 75% relative humidity;

10 [0052] Figure 7 illustrates plasma concentration versus time curves for Compound (1-1) after 1 mg/kg intravenous dosing (solid rectangles) and 3 mg/kg oral dosing as 25% Compound (1-1):PVP (open circles), 25% Compound (1-1):HPMCAS-MG (open triangles), and 50% Compound (1-1):HPMCAS-MG (open inverted triangles). The inset depicts the same data plotted on a semilogarithmic scale;

15 [0053] Figure 8 illustrates plasma concentration versus time curves for Compound (1-1) after 3 mg/kg oral dosing as 25% Compound (1-1):PVP (open circles), 25% Compound (1-1):HPMCAS-MG (open triangles), and 50% Compound (1-1):HPMCAS-MG (open inverted triangles). The inset depicts the same data plotted on a semi-logarithmic scale;

20 [0054] Figure 9 illustrates a powder X-ray diffraction profile of solid dispersions of compound (1-1) in HPMCAS-MG at time zero of a stability test;

[0055] Figure 10 illustrates a powder X-ray diffraction profile of solid dispersions of compound (1-1) in HPMCAS-MG after 1 month at 40 °C and 75 % relative humidity;

25 [0056] Figure 11 illustrates a powder X-ray diffraction profile of solid dispersions of compound (1-1) in HPMCAS-MG after 2 months at 40 °C and 75 % relative humidity; and

[0057] Figure 12 illustrates a powder X-ray diffraction profile of solid dispersions of compound (1-1) in HPMCAS-MG after 3 month at 40 °C and 75 % relative humidity.

[0058]

DETAILED DESCRIPTION OF THE INVENTION

25 [0059] The present subject matter will now be described more fully hereinafter with reference to the accompanying Figures and Examples, in which representative embodiments are shown. The present subject matter can, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided to describe and enable one of skill in the art. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the subject matter pertains. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entireties.

I. Definitions:

[0060] The term “alkyl group” as used herein refers to a saturated straight or branched hydrocarbon.

5 [0061] The term “substituted alkyl group” refers to an alkyl moiety having one or more substituents replacing a hydrogen or one or more carbons of the hydrocarbon backbone.

10 [0062] The term “alkenyl group” whether used alone or as part of a substituent group, for example, “C₁₋₄alkenyl(aryl),” refers to a partially unsaturated branched or straight chain monovalent hydrocarbon radical having at least one carbon—carbon double bond, whereby the double bond is derived by the removal of one hydrogen atom from each of two adjacent carbon atoms of a parent alkyl molecule and the radical is derived by the removal of one hydrogen atom from a single carbon atom. Atoms may be oriented about the double bond in either the cis (Z) or trans (E) conformation. Typical alkenyl radicals include, but are not limited to, ethenyl, propenyl, allyl(2-propenyl), butenyl and the like. Examples include C₂₋₈alkenyl or C₂₋₄alkenyl groups.

15 [0063] The term “C_(j-k)” (where *j* and *k* are integers referring to a designated number of carbon atoms) refers to an alkyl, alkenyl, alkynyl, alkoxy or cycloalkyl radical or to the alkyl portion of a radical in which alkyl appears as the prefix root containing from *j* to *k* carbon atoms inclusive. For example, C₍₁₋₄₎ denotes a radical containing 1, 2, 3 or 4 carbon atoms.

[0064] The terms “halo” or “halogen” as used herein refer to F, Cl, Br, or I.

20 [0065] The term “pharmaceutically acceptable salts” is art-recognized and refers to the relatively non-toxic, inorganic and organic acid addition salts, or inorganic or organic base addition salts of compounds, including, for example, those contained in compositions of the present invention.

[0066] The term “solid dispersion” as used herein refers to a group of solid products consisting of at least two different components, generally a hydrophilic carrier and a hydrophobic drug (active ingredient).

25 [0067] The term “chiral” is art-recognized and refers to molecules that have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. A “prochiral molecule” is a molecule that has the potential to be converted to a chiral molecule in a particular process.

30 [0068] The symbol “—” is used to denote a bond that may be a single, a double or a triple bond.

[0069] The term “enantiomer” as it used herein, and structural formulas depicting an enantiomer are meant to include the “pure” enantiomer free from its optical isomer as well as mixtures of the

enantiomer and its optical isomer in which the enantiomer is present in an enantiomeric excess, e.g., at least 10%, 25%, 50%, 75%, 90%, 95%, 98%, or 99% enantiomeric excess.

[0070] The term “stereoisomers” when used herein consist of all geometric isomers, enantiomers or diastereomers. The present invention encompasses various stereoisomers of these compounds and mixtures thereof. Conformational isomers and rotamers of disclosed compounds are also contemplated.

[0071] The term “stereoselective synthesis” as it is used herein denotes a chemical or enzymatic reaction in which a single reactant forms an unequal mixture of stereoisomers during the creation of a new stereocenter or during the transformation of a pre-existing one, and are well known in the art. Stereoselective syntheses encompass both enantioselective and diastereoselective transformations. For examples, see Carreira, E. M. and Kvaerno, L., *Classics in Stereoselective Synthesis*, Wiley-VCH: Weinheim, 2009.

[0072] The term “spray drying” refers to processes which involve the atomization of the feed suspension or solution into small droplets and rapidly removing solvent from the mixture in a processor chamber where there is a strong driving force for the evaporation (e.g., hot dry gas or partial vacuum or combinations thereof).

[0073] The term “therapeutically effective amount” as used herein refers to any amount of a thienotriazolodiazepine of the present invention or any other pharmaceutically active agent which, as compared to a corresponding a patient who has not received such an amount of the thienotriazolodiazepine or the other pharmaceutically active agent, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder.

[0074] The term “about” means +/- 10%.

[0075] Throughout this application and in the claims that follow, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, should be understood to imply the inclusion of a stated integer step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

[0076] It has now been found that thienotriazolodiazepine compound of Formula (1), described herein below, can be formulated as a solid dispersion with pharmaceutically acceptable polymers, to provide an oral formulation that provides high absorption of the pharmaceutical ingredient into the

circulation from the gastrointestinal tract. In one embodiment, the pharmaceutically acceptable polymer is hypromellose acetate succinate (also called hydroxypropylmethylcellulose acetate succinate or HPMCAS). In one embodiment, the pharmaceutically acceptable polymer is polyvinylpyrrolidone (PVP).

5 [0077] In some embodiments, the hydroxypropylmethyl cellulose acetate succinates (HPMCAS), may include M grade having 9% acetyl/11% succinoyl (e.g., HPMCAS having a mean particle size of 5 μm (i.e., HPMCAS-MF, fine powder grade) or having a mean particle size of 1 mm (i.e., HPMCAS-MG, granular grade)), H grade having 12% acetyl/6% succinoyl (e.g., HPMCAS having a mean particle size of 5 μm (i.e., HPMCAS-HF, fine powder grade) or having a mean particle size of 1 mm (i.e., HPMCAS-HG, granular grade)), and L grade having 8% acetyl/15% succinoyl (e.g., HPMCAS having a mean particle size of 5 μm (i.e., HPMCAS-LF, fine powder grade) or having a mean particle size of 1 mm (i.e., HPMCAS-LG, granular grade)).

10

15 [0078] In some embodiments, the polyvinyl pyrrolidones may have molecular weights of about 2,500 (Kollidon® 12 PF, weight-average molecular weight between 2,000 to 3,000), about 9,000 (Kollidon® 17 PF, weight-average molecular weight between 7,000 to 11,000), about 25,000 (Kollidon® 25, weight-average molecular weight between 28,000 to 34,000), about 50,000 (Kollidon® 30, weight-average molecular weight between 44,000 to 54,000), and about 1,250,000 (Kollidon® 90 or Kollidon® 90F, weight-average molecular weight between 1,000,000 to 1,500,000).


20 II. Methods of Treatment

[0079] In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer using the compositions described herein.

25 [0080] In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer in a mammal comprising: administering to a patient in need a pharmaceutically acceptable amount of a composition comprising a solid dispersion according to any of the compositions described in Sections III, IV, V and VI described herein.

30 [0081] In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer in a mammal comprising: administering to a patient in need a pharmaceutically acceptable amount of a composition comprising a pharmaceutical formulation according to any of the compositions described in Sections III, IV, V and VI described herein.

[0082] In some embodiments, methods of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer use thienotriazolodiazepine compound of the Formula (1)




5

[0083] wherein

R¹ is alkyl having a carbon number of 1-4, R² is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, R³ is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; —NR⁵—(CH₂)_m—R⁶ wherein R⁵ is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and R⁶ is phenyl or pyridyl optionally substituted by a halogen atom; or —NR⁷—CO—(CH₂)_n—R⁸ wherein R⁷ is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and R⁸ is phenyl or pyridyl optionally substituted by a halogen atom, and R⁴ is —(CH₂)_a—CO—NH—R⁹ wherein a is an integer of 1-4, and R⁹ is alkyl having a carbon number of 1-4; hydroxyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group or —(CH₂)_b—COOR¹⁰ wherein b is an integer of 1-4, and R¹⁰ is alkyl having a carbon number of 1-4, including any salts, isomers, enantiomers, racemates, hydrates, solvates, metabolites, and polymorphs thereof.

[0084] In some embodiments, Formula (1) is selected from Formula (1A):



[0085]

wherein X is a halogen, R¹ is C₁-C₄ alkyl, R² is C₁-C₄ alkyl, a is an integer of 1-4, R³ is C₁-C₄ alkyl, C₁-C₄ hydroxyalkyl, C₁-C₄ alkoxy, phenyl optionally having substituent(s), or heteroaryl optionally having substituent(s), a pharmaceutically acceptable salt thereof or a hydrate thereof; and a pharmaceutically acceptable polymer. In one such embodiment, the thienotriazolodiazepine compound is formulated as a solid dispersion comprising an amorphous thienotriazolodiazepine compound.

[0086] In some embodiments, the present disclosure provides for methods of treating medulloblastoma in a mammal comprising: administering to a patient in need a pharmaceutically acceptable amount of a composition comprising a pharmaceutical formulation according to any of the compositions described in Sections III, IV, V and VI described herein.

[0087] Medulloblastoma (also referred to as an infratentorial primitive neuroectodermal tumor (PNET)) can be any tumor that originates in the cerebellum (or posterior fossa) of the brain.

[0088] Medulloblastomas include, but are not limited to, classic medulloblastoma, desmoplastic nodular medulloblastomas, large-cell medulloblastomas, medulloblastomas with neuroblastic or neuronal differentiation, medulloblastomas with glial differentiation, medulloblastomas, and melanotic medulloblastomas. Classic medulloblastoma tissue can be characterized by densely packed, small round cells with large dark nuclei. Desmoplastic nodular medulloblastoma can be characterized by islands of densely packed tumor cells intermixed with looser, less cellular areas. Large-cell medulloblastoma (also referred to as anaplastic medulloblastoma) can be characterized by large round tumor cells.

[0089] Medulloblastomas include, but are not limited to Wnt, Shh, Group 3, and Group 4 medulloblastomas. Wnt refers to a subtype of medulloblastomas that, without being limited by a particular theory of operation, may involve the Wnt signaling pathway in its pathogenesis. Wnt includes, but is not limited to Wnt α and Wnt β medulloblastomas. Shh (also referred to as Sonic Hedgehog) refers to a subtype of medulloblastomas that, without being limited by a particular theory of operation, may involve the Shh signaling pathway in its pathogenesis. Shh includes, but is not limited to Shh α , Shh β and Shh γ medulloblastomas.

[0090] In some embodiments, the present disclosure provides for methods of treating ALK+ non-small cell lung cancer in a mammal comprising: administering to a patient in need a pharmaceutically acceptable amount of a composition comprising a pharmaceutical formulation according to any of the compositions described in Sections III, IV, V and VI described herein.

5 [0091] ALK + non-small cell lung cancer refers to any non-small cell lung cancer in which the ALK gene is active. The ALK gene can be understood to be active if the ALK+ non-small cell lung cancer is characterized by tumor cells having greater than about 15% ALK positivity as determined using, for example, fluorescence in situ hybridization (FISH). However, in some embodiments a tumor cells having greater than about 10% ALK positivity can be understood to be ALK +.

10 [0092] Without being limited by a particular theory, the ALK gene can be activated to cause cancer when it is fused with another nearby gene. In some embodiments, ALK +non-small cell lung cancer includes EML4-ALK rearrangement, which, without being limited by a particular theory, arises from fusion between the 5' end of the EML4 gene and the 3' end of the ALK gene on chromosome 2p33. In other embodiments, ALK+ non-small cell lung cancer is characterized by 15 fusion of the ALK gene with the KIF5B, TFG, or KLC1 genes.

[0093] In some embodiments, the present disclosure provides for methods of treating resistant non-Hodgkin lymphoma in a mammal comprising: administering to a patient in need a pharmaceutically acceptable amount of a composition comprising a pharmaceutical formulation according to any of the compositions described in Sections III, IV, V and VI described herein.

20 [0094] In some embodiments of the method, the non-Hodgkin lymphoma is resistant to treatment by one or more anti-cancer drugs excluding a thienotriazolodiazepine compound represented by Formula (1). Such non-Hodgkin lymphoma is also referred to herein as “resistant non-Hodgkin lymphoma.”

25 [0095] In some embodiments of the methods of treating resistant non-Hodgkin lymphoma in a mammal, the resistant non-Hodgkin lymphoma in the mammal is a B-cell non-Hodgkin lymphoma. B-cell non-Hodgkin lymphomas include, but are not limited to, Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma. In other embodiments the resistant non-Hodgkin lymphoma 30 is a T-cell non-Hodgkin lymphoma. T-cell non-Hodgkin lymphomas include, but are not limited to, mycosis fungoides, anaplastic large cell lymphomas, and precursor T-lymphoblastic lymphoma. In preferred embodiments, the non-Hodgkin lymphoma is DLBCL or mantle cell lymphoma.


[0096] In some embodiments, methods of treating resistant non-Hodgkin lymphoma in a mammal comprise administering a pharmaceutically acceptable amount of a composition to a patient wherein the composition comprises: (1) any of the thienotriazolodiazepine compositions described in Sections III, IV, or V herein; and (2) an mTOR inhibitor, a BTK inhibitor, an HDAC inhibitor, an anti-CD20 monoclonal antibody, DNA methyltransferase inhibitor and an immunomodulator, or a combination thereof.







[0097] In some embodiments, methods of treating resistant non-Hodgkin lymphoma use a thienotriazolodiazepine compound of the Formula (1) in combination with an mTOR inhibitor, a BTK inhibitor, an HDAC inhibitor, an anti-CD20 monoclonal antibody, DNA methyltransferase inhibitor, an immunomodulator, or a combination thereof. In some embodiments, methods of treating resistant non-Hodgkin lymphoma use a thienotriazolodiazepine compound of the Formula (1A) in combination with an mTOR inhibitor, a BTK inhibitor, an HDAC inhibitor, an anti-CD20 monoclonal antibody, DNA methyltransferase inhibitor, an immunomodulator, or a combination thereof.

[0098] The thienotriazolodiazepine composition and the mTOR inhibitor (or BTK inhibitor, HDAC inhibitor, anti-CD20 monoclonal antibody, DNA methyltransferase inhibitor, or immunomodulator) can be administered either simultaneously or sequentially. In some embodiments the combination can produce a synergistic effect.

[0099] Example suitable BTK inhibitor drugs for use in combinations with the thienotriazolodiazepine compounds of Formula (1) in the methods of treating resistant non-Hodgkin lymphoma of the present invention include the BTK inhibitors listed in the below Table A.

[0100] Table A.

Inhibitor Name	Inhibitor Information	Literature Citations
PCI-32765 (Ibrutinib)	<p>PCI-32765 (Ibrutinib) is a potent and highly selective Btk inhibitor with IC₅₀ of 0.5 nM.</p> 	<p>Cancer Cell, 2012, 22(5):656-67. Blood, 2012, 120(19), 3978-3985; Cell Signal, 2013, 25(1):106-12.</p>
GDC-0834	<p>GDC-0834 is a novel potent and selective BTK inhibitor with IC₅₀ of 5.9</p>	<p>J. Hematol. Oncol. 2013 Aug 19; 6:59;</p>

Inhibitor Name	Inhibitor Information	Literature Citations
	nM.	
RN-486 		J. Hematol. Oncol. 2013 Aug 19; 6:59;
CGI-560 		J. Hematol. Oncol. 2013 Aug 19; 6:59;
CGI-1746 		J. Hematol. Oncol. 2013 Aug 19; 6:59;
LFM-A13 	Bruton's tyrosine kinase (BTK) inhibitor IC50= 2.5 μ M. IC50's for JAK-1, JAK-2, JAK-3, SYK, HCK, EGFR kinase, IR kinase all >300 μ M	J. Hematol. Oncol. 2013 Aug 19; 6:59;
Terreic acid  (1R,6S)-3-Hydroxy-4-methyl-7-oxabicyclo[4.1.0]hept-3-ene-2,5-dione	Selective inhibitor of Bruton's tyrosine kinase (BTK). Inhibits the catalytic activity of BTK as well as the interaction between BTK and PKC β II, in intact cells and in cell-free systems, without affecting the	




Inhibitor Name	Inhibitor Information	Literature Citations
	activity of PKC. Terreic acid has little or no effect on the activities of Lyn, Syk, PKA, casein kinase I, ERK1, ERK2 and p38 kinase. A useful tool in studying the role of BTK in cellular signaling.	
CC-292		J. Pharmacol. Exp. Ther. 2013 Aug; 346(2): 219-228; Leukemia 2014 Mar 7 (epub); J. Hematol. Oncol. 2013 Aug 19; 6:59;
CNX-774		J. Hematol. Oncol. 2013 Aug 19; 6:59;
Dasatinib		N Eng J Med; 2006 Jun 15; 354(24): 2531-41
QL47		ACS Chem Biol; 2013 Mar 17

[00101] Example suitable mammalian target of rapamycin (mTOR) inhibitors for use in combinations with the thienotriazolodiazepine of Formula (1) in the methods of treating resistant non-Hodgkin lymphoma of the present invention include, but are not limited to, the mTOR inhibitors listed in the below Table B.





[00102] Table B.

No.	Inhibitor Name	Description	Literature Citations
-----	----------------	-------------	----------------------





No.	Inhibitor Name	Description	Literature Citations
1	BEZ235 (NVP-BEZ235)	BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor of p110 α , p110 γ , p110 δ and p110 β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM, respectively, and also inhibits ATR with IC50 of 21 nM.	Nature, 2012, 487(7408):505-9;Blood, 2011, 118(14), 3911-3921;Cancer Res, 2011, 71(15), 5067-5074.
2	Everolimus (RAD001)	Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM.	Cell, 2012, 149(3):656-70;;Cancer Cell, 2012, 21(2), 155-167; Clin Cancer Res, 2013, 19(3):598-609.
3	Rapamycin (Sirolimus, AY22989, NSC226080)	Rapamycin (Sirolimus, AY-22989, WY-090217) is a specific mTOR inhibitor with IC50 of ~0.1 nM.	Cancer Cell, 2011, 19(6), 792-804;;Cancer Res, 2013, ;Cell Res, 2012, 22(6):1003-21.
4	AZD8055	AZD8055 is a novel ATP-competitive inhibitor of mTOR with IC50 of 0.8 nM.	Autophagy, 2012, Am J Transplant, 2013, ;Biochem Pharmacol, 2012, 83(9), 1183-1194
5	PI-103 3-[4-(4-Morpholinylpyrido[3',2':4,5]f-uro[3,2-d]pyrimidin-2-yl]phenol	PI-103 is a potent, ATP-competitive PI3K inhibitor of DNA-PK, p110 α , mTORC1, PI3KC2 β , p110 δ , mTORC2, p110 β , and p110 γ with IC50 of 2 nM, 8 nM, 20 nM, 26 nM, 48 nM, 83 nM, 88 nM and 150 nM, respectively.	Leukemia, 2013, 27(3):650-60;Leukemia, 2012, 26(5):927-33;Biochem Pharmacol, 2012, 83(9), 1183-1194.
6	Tensirolimus (CCI-779, NSC-683864)	Tensirolimus (CCI-779, Torisel) is a specific	Autophagy, 2011, 7(2), 176-




No.	Inhibitor Name	Description	Literature Citations
		mTOR inhibitor with IC50 of 1.76 μ M.	187;Tuberc Respir Dis (Seoul), 2012, 72(4), 343-351;PLoS One, 2013, 8(5):e62104.
7	Ku-0063794	 <p>rel-5-[2-[(2R,6S)-2,6-dimethyl-4-mo-rpholinyl]-4-(4-morpholinyl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxybenzenemethanol</p>	KU-0063794 is a potent and highly specific mTOR inhibitor for both mTORC1 and mTORC2 with IC50 ~10 nM.
8	GDC-0349		GDC-0349, is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM.
9	Torin 2	 <p>9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H)-one</p>	Torin 2 is a highly potent and selective mTOR inhibitor with IC50 of 0.25 nM, and also exhibits potent cellular activity against ATM/ATR/DNA-PK with EC50 of 28 nM, 35 nM and 118 nM, respectively.
10	INK 128 (MLN-0128)	INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM.	

No.	Inhibitor Name	Description	Literature Citations
11	AZD2014	 AZD2014 is a novel dual mTORC1 and mTORC2 inhibitor with potential antineoplastic activity.	
12	NVP-BGT226(BGT226)	 NVP-BGT226 is a novel dual PI3K/mTOR inhibitor with IC50 of 1 nM.	
13	PF-04691502	 PF-04691502 is an ATP-competitive, selective inhibitor of PI3K($\alpha/\beta/\delta/\gamma$)/mTOR with Ki of 1.8 nM/2.1 nM/1.6 nM/1.9 nM and 16 nM, also inhibits Akt phosphorylation on T308/S473 with IC50 of 7.5 nM/3.8 nM.	
14	CH5132799	 CH5132799 exhibits a strong inhibitory activity especially against PI3K α with IC50 of 14 nM and also inhibits mTOR with IC50 of 1.6 μ M.	

No.	Inhibitor Name	Description	Literature Citations
15	GDC-0980 (RG7422)	 <p>GDC-0980 (RG7422) is a potent, selective inhibitor of PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ with IC50 of 5 nM, 27 nM, 7 nM, and 14 nM, and also a mTOR inhibitor with Ki of 17 nM.</p>	
16	Torin 1	 <p>1-[4-[4-(1-Oxopropyl)-1-piperazinyl]-3-(trifluoromethyl)phenyl]-9-(3-quinolinyl)-benz-o[h]-1,6-naphthyridin-2(1H)-one</p> <p>Torin1 is a potent inhibitor of mTOR with IC50 of 2-10 nM.</p>	
17	WAY-600	 <p>WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM.</p>	
18	WYE-125132(WYE-132)	 <p>WYE-125132 is a highly potent, ATP-competitive and specific mTOR inhibitor with IC50 of 0.19 nM.</p>	
19	WYE-687	<p>WYE-687 is an ATP-competitive and</p>	

No.	Inhibitor Name	Description	Literature Citations
		selective inhibitor of mTOR with IC50 of 7 nM.	
20	GSK2126458(GSK458) 	GSK2126458 is a highly selective and potent inhibitor of p110 α , p110 β , p110 γ , p110 δ , mTORC1 and mTORC2 with Ki of 0.019 nM, 0.13 nM, 0.024 nM, 0.06 nM, 0.18 nM and 0.3 nM, respectively.	
21	PF-05212384 (PKI-587) 	PKI-587 is a highly potent dual inhibitor of PI3K α , PI3K γ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM, respectively.	
22	PP-121 	PP-121 is a multi-target inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, respectively, and also inhibits DNA-PK with IC50 of 60 nM. 1-Cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine	
23	OSI-027(ASP4786)	OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM,	Exp Eye Res, 2013, 113C, 9-18


No.	Inhibitor Name	Description	Literature Citations
		respectively.	
24	Palomid 529(P529)	 Palomid 529 inhibits both the mTORC1 and mTORC2 complexes, reduces phosphorylation of pAktS473, pGSK3βS9, and pS6 but neither pMAPK nor pAktT308. Phase 1.	
25	PP242  2-[4-Amino-1-(1-methylethyl)-1H-pyr-azolo[3,4-d]pyrimidin-3-yl]-1H-indol-5-ol	PP242 is a selective mTOR inhibitor with IC50 of 8 nM.	Autophagy, 2012, 8(6), 903-914
26	XL765(SAR245409) 	XL765 is a dual inhibitor of mTOR/PI3k for mTOR, p110 α , p110 β , p110 γ and p110 δ with IC50 of 157 nM, 39 nM, 113 nM, 9 nM and 43 nM, respectively.	Endocrinology, 2013, 154(3):1247-59
27	GSK1059615	GSK1059615 is a novel and dual inhibitor of PI3K α , PI3K β , PI3K δ , PI3K γ and mTOR with IC50 of 0.4 nM, 0.6 nM, 2 nM, 5 nM and 12 nM, respectively.	Nature, 2012, 486(7404), 532-536





No.	Inhibitor Name	Description	Literature Citations
	 5-[[4-(4-Pyridinyl)-6-quinolinyl]methylene]-2,4-thiazolidenedione		
28	WYE-354 	WYE-354 is a potent, specific and ATP-competitive inhibitor of mTOR with IC50 of 5 nM.	Mol Cancer Res, 2012, 10(6), 821-833.
29	Deforolimus (Ridaforolimus, MK-8669) 	Deforolimus (Ridaforolimus; AP23573; MK-8669; 42-(Dimethylphosphinate) rapamycin; Ridaforolimus) is a selective mTOR inhibitor with IC50 of 0.2 nM.	Mol Genet Meta, 2010, 100(4), 309-315.





[00103] Example suitable histone deacetylase (HDAC) inhibitors for use in combinations with the thienotriazolodiazepine of Formula (1) in the methods of treating resistant non-Hodgkin lymphoma of the present invention include, but are not limited to, the HDAC inhibitors listed in the below Table C.




5 [00104] Table C.



Inhibitor Name	Inhibitor Information	Literature Citations
Vorinostat (SAHA, MK0683)	Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is an HDAC inhibitor with IC50 of ~10 nM.	Nature, 2011, 471(7337):235-9; Nat

Inhibitor Name	Inhibitor Information	Literature Citations
		Biotechnol, 2011, 29(3), 255-265; J Exp Med, 2012, 209(1):35-50.
Entinostat (MS-275, SNDX-275)	MS-275 is an HDAC inhibitor of HDAC1 and HDAC3 with IC50 of 0.51 μ M and 1.7 μ M, respectively.	Nat Biotechnol, 2011, 29(3), 255-265; Proc Natl Acad Sci U S A, 2011, 108(49):19629-34; Circ Res, 2012, 110(5):739-48.
Panobinostat (LBH589, NVP-LBH589)	LBH589 (Panobinostat) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM and 20 nM in MOLT-4 and Reh cells, respectively.	Nat Biotechnol, 2011, 29(3), 255-265; Blood, 2012, 119(6):1450-8; Acta Neuropathol, 2011, 122(5):637-50
Trichostatin A (TSA)	Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM.	Plant J, 2013, 74(5), 815-828; Epigenetics, 2012, 7(10), 1161-1172.
Mocetinostat (MGCD0103, MG0103)	 <p>MGCD0103 (Mocetinostat) is a potent HDAC inhibitor for HDAC1, HDAC2 and HDAC3 with IC50 of 0.15 μM, 0.29 μM and 1.66 μM, respectively.</p>	Nat Struct Mol Biol, 2013, 20(3):317-25; Circ Res, 2012, 110(5):739-48; Oncogene, 2011, 30(27), 3062-3072.
Belinostat (PXD101)	Belinostat (PXD101) is a novel HDAC inhibitor with IC50 of 27 nM in HeLa cell extracts.	Nat Biotechnol, 2011, 29(3), 255-265; Breast Cancer Res Treat, 2011, 131(3), 777-789; PLoS One, 2011, 6(2), e17138.
MC1568	MC1568 is a selective HDAC inhibitor	Proc Natl Acad

Inhibitor Name	Inhibitor Information	Literature Citations
	with IC ₅₀ of 220 nM.	Sci U S A, 2012, 109(34):E2284 -93; Oncogene, 2013, ; J Biol Chem, 2011, 286(27), 23842-23851.
LAQ824 (NVP-LAQ824, Dacinostat)	 <p>LAQ824 (NVP-LAQ824) is a novel HDAC inhibitor with IC₅₀ of 32 nM.</p>	Nat Biotechnol, 2011, 29(3), 255-265; Diabetologia, 2012, 55(9):2421-31; Mol Pain, 2010, 6, 51.
ITF2357 (Givinostat)	ITF2357 (Givinostat) is a potent inhibitor of HDAC with IC ₅₀ of 7.5-16 nM.	J Neurosci, 2013, 33(17), 7535-7547.
Tubastatin A HCl	 <p>Tubastatin A is a potent HDAC6 inhibitor with IC₅₀ of 15 nM.</p>	
CUDC-101	 <p>CUDC-101 is a potent multi-target inhibitor targeting HDAC, EGFR and HER2 with IC₅₀ of 4.4 nM, 2.4 nM, and 15.7 nM, respectively.</p>	
SB939 (Pracinostat)	 <p>SB939 is a potent HDAC inhibitor with IC₅₀ of 40-140 nM.</p>	Antimicrob Agents Chemother, 2012, 56(7), 3849-3856
Droxinostat	Droxinostat (CMH, 5809354) is a	Nat Struct Mol

Inhibitor Name	Inhibitor Information	Literature Citations
 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide	selective inhibitor of HDAC3, HDAC6 and HDAC8 with IC50 of 16.9 μ M, 2.47 μ M and 1.46 μ M, respectively.	Biol, 2013, 20(3):317-25
 N-hydroxy-2-((4-((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide	JNJ-26481585 (Quisinostat) is an HDAC inhibitor for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11 with IC50 of 0.11 nM, 0.33 nM, 0.64 nM, 0.46 nM and 0.37 nM, respectively.	
PCI-24781(CRA-024781)	PCI-24781 (CRA-024781) is a novel broad spectrum HDAC inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 and HDAC10 with Ki of 7 nM, 19 nM, 8.2 nM, 17 nM, 280 nM, 24 nM, respectively.	PLoS One, 2013, 8(5), e65369; Nat Biotechnol, 2011, 29(3), 255-265.
 Romidepsin (FK228, depsipeptide)	Romidepsin (FK228, FR901228, depsipeptide, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM, respectively. (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(1methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16ene-3,6,9,19,22-pentone	J Neurosci, 2013, 33(17):7535-7547; Br J Haematol, 2013.
 (S)-N-hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide	AR-42 (HDAC-42, OSU-HDAC42) is a pan-HDAC inhibitor with IC50 30 nM.	
Valproic acid sodium salt (Sodium	Valproic acid sodium salt (Sodium	J Neurosci,

Inhibitor Name	Inhibitor Information	Literature Citations
valproate)	valproate) is a HDAC inhibitor with IC50 of 0.4 mM and also inhibits GABA-transaminase or succinic semialdehyde dehydrogenase.	2013, 33(17), 7535-7547.
PCI-34051	PCI-34051 is a potent and specific HDAC8 inhibitor with IC50 of 10 nM.	
CI994 (Tacedinaline)	<p>CI994 (Tacedinaline) is an anti-cancer drug which inhibits HDAC1 with IC50 of 0.57 μM.</p> 	
M344	M344 is a potent HDAC inhibitor with IC50 of 100 nM.	
PI3K/HDAC Inhibitor I	PI3K/HDAC Inhibitor I is a dual PI3K and HDAC inhibitor for PI3K α , HDAC1, HDAC2, HDAC3 and HDAC10 with IC50 of 19 nM, 1.7 nM, 5 nM, 1.8 nM and 2.8 nM, respectively.	
Rocilinostat (ACY-1215)	<p>Rocilinostat (ACY-1215) is a selective HDAC6 inhibitor with IC50 of 5 nM.</p> 	
Apicidin (OSI-2040)	<p>Apicidin is a potent HDAC inhibitor with IC50 of 0.7 nM.</p> <p>(3S,6S,9S,15aR)-9-((R)-sec-butyl)-6-((1-methoxy-1H-indol-2-yl)methyl)-3-(6-oxooctyl)decahydro-1H-pyrido[1,2-a][1,4,7,10]tetraazacyclododecene-1,4,7,10(12H)-tetraone</p> 	
Scriptaid	Scriptaid is an inhibitor of HDAC.	
Tubastatin A	Tubastatin A is a potent and selective inhibitor of HDAC6 with IC50 of 15 nM.	J Biol Chem, 2013, 288(20), 14400-7.

Inhibitor Name	Inhibitor Information	Literature Citations
 N-hydroxy-4-((2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)methyl)benzamide hydrochloride		
Sodium Phenylbutyrate 	Sodium Phenylbutyrate is a transcriptional regulators that act by altering chromatin structure via the modulation of HDAC activity.	
Resminostat (RAS2410) 	(E)-3-((4-((dimethylamino)methyl)phenylsulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide	

[00105] Example suitable anti-CD20 monoclonal antibodies for use in combinations with the thienotriazolodiazepine compounds of Formula (1) in the methods of treating resistant non-Hodgkin lymphoma of the present invention include the anti-CD20 monoclonal antibodies listed in the below 5 Table D.

[00106] Table D.



No.	Inhibitor Name	Format	Manufacturer
1	Rituximab	Chimeric IgG1	Genentech/Biogen
2	Y^{90} -Ibritumomab tiuxetan	Murine (90Y)	iogen/IDEC
3	I^{131} I tositumomab	Murine (131I)	GSK
4	Ofatumumab	Human IgG1	Genmab AC/GSK
5	Ocrelizumab	Humanized IgG1	Genentech/Roche/Biogen
6	TRU-015	Small modular immunopharmaceutical (SMIP TM) drug composed of human	Trubion Pharma/Wyeth


No.	Inhibitor Name	Format	Manufacturer
		IgG1 Fc and hinge regions (hinge, CH ₂ , and CH ₃) linked directly to an anti-CD20 scFv	
7	Veltuzumab	Humanized	Immunomedics
8	AME-133v	Humanized IgG1	Applied Molecular Evolution/Eli Lilly
9	PRO131921 humanized (Version 114)	IgG1	Genentech
10	GA101	Humanized IgG1	Glycart/Roche

[00107] In some embodiments, the immunomodulatory agent can be selected from the group consisting of thalidomide, lenalidomide, pomalidomide, and esters, derivatives, prodrugs, salts, and complexes thereof.

5 [00108] Suitable immunomodulatory agents for use in combinations with the thienotriazolodiazepine compounds of Formula (1) in the methods of the present invention include the immunomodulatory agents listed in the below Table E.



[00109] Table E:





No.	Immunomodulatory Agent Name	Structure
1	thalidomide (Inmunoprin, Talidex, Talizer, Thalomid)	
2	lenalidomide (CC-5013, Revlimid)	

No.	Immunomodulatory Agent Name	Structure
3	pomalidomide (CC-4047, Pomalyst)	

[00110] Example DNA methyltransferase inhibitors for use in combinations with the thienotriazolodiazepine compounds of Formula (1) in the methods of the present invention include the compounds listed in the below Table F. An example suitable DNA methyltransferase inhibitor for use in combinations with the thienotriazolodiazepine compounds of Formula (1) in the methods of 5 treating resistant non-Hodgkin lymphoma of the present invention includes decitabine.

[00111] Table F:

Inhibitor Name	Inhibitor Information	Literature Citations
decitabine (5-aza-2'-deoxycytidine)		J Natl Cancer Inst 2005;97:1498-1506
5-azacytidine		Experientia 1964; 20:202-3; Cell 1980; 20:85-93; J Natl Cancer Inst 2005;97:1498-1506
zebularin		J Natl Cancer Inst 2005;97:1498-1506

Inhibitor Name	Inhibitor Information	Literature Citations
		
RG108 		J Natl Cancer Inst 2005;97:1498-1506
epigallocatechin-3-gallate (EGCG) 		J Natl Cancer Inst 2005;97:1498-1506
procaine 		J Natl Cancer Inst 2005;97:1498-1506


[00112] A mammalian subject as used herein can be any mammal. In one embodiment, the mammalian subject includes, but is not limited to, a human; a non-human primate; a rodent such as a mouse, rat, or guinea pig; a domesticated pet such as a cat or dog; a horse, cow, pig, sheep, goat, or rabbit. In one embodiment, the mammalian subject includes, but is not limited to, a bird such as a duck,

goose, chicken, or turkey. In one embodiment, the mammalian subject is a human. In one embodiment, the mammalian subject can be either gender and can be any age.

5 [00113] In the present invention, “treatment” or “treat” refers to an act or the action of administration of the active ingredient of the present invention to a person diagnosed by a doctor to have resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer or be at risk of developing resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-
10 small cell lung cancer (patient), which aims, for example, to alleviate the resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer (or symptom of the same), prevent the onset of the resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non- small cell lung cancer (or symptom of the same), or restore the state before onset of the resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer.

III. Thienotriazolodiazepine Compounds:

[00114] In one embodiment, the thienotriazolodiazepine compounds, used in the formulations of the present invention, are represented by Formula (1):



15 [00115] wherein

R¹ is alkyl having a carbon number of 1-4, R² is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, R³ is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; —NR⁵—(CH₂)_m—R⁶ wherein R⁵ is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and R⁶ is phenyl or pyridyl optionally substituted by a halogen atom; or —NR⁷—CO—(CH₂)_n—R⁸ wherein R⁷ is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and R⁸ is phenyl or pyridyl optionally substituted by a halogen atom, and R⁴ is —(CH₂)_a—CO—NH—R⁹ wherein a is an integer of 1-4, and

R⁹ is alkyl having a carbon number of 1-4; hydroxyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group or —(CH₂)_b—COOR¹⁰ wherein b is an integer of 1-4, and R¹⁰ is alkyl having a carbon number of 1-4, 5 including any salts, isomers, enantiomers, racemates, hydrates, solvates, metabolites, and polymorphs thereof.

[00116] In one embodiment, a suitable alkyl group includes linear or branched alkyl radicals including from 1 carbon atom up to 4 carbon atoms. In one embodiment, a suitable alkyl group includes linear or branched alkyl radicals including from 1 carbon atom up to 3 carbon atoms. In one 10 embodiment, a suitable alkyl group includes linear or branched alkyl radicals include from 1 carbon atom up to 2 carbon atoms. In one embodiment, exemplary alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl. In one embodiment, exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, and 2-methyl-2-propyl.

[00117] In some embodiments, the present invention provides pharmaceutically acceptable salts, 15 solvates, including hydrates, and isotopically-labeled forms of the thienotriazolodiazepine compounds described herein. In one embodiment, pharmaceutically acceptable salts of the thienotriazolodiazepine compounds include acid addition salts formed with inorganic acids. In one embodiment, pharmaceutically acceptable inorganic acid addition salts of the thienotriazolodiazepine include salts of hydrochloric, hydrobromic, hydroiodic, phosphoric, metaphosphoric, nitric and sulfuric acids. In one embodiment, pharmaceutically acceptable salts of the thienotriazolodiazepine compounds include acid addition salts formed with organic acids. In one 20 embodiment, pharmaceutically acceptable organic acid addition salts of the thienotriazolodiazepine include salts of tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, formic, propionic, glycolic, gluconic, maleic, succinic, camphorsulfuric, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, stearic, sulfinilic, alginic, galacturonic and arylsulfonic, for example benzenesulfonic and 4-methyl benzenesulfonic acids.

[00118] The present invention provides pharmaceutically acceptable isotopically-labeled forms of the thienotriazolodiazepine compounds, described herein, wherein one or more atoms are replaced 30 by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in

the thienotriazolodiazepine compounds include isotopes of hydrogen, e.g., ^2H and ^3H , carbon, e.g., ^{11}C , ^{13}C and ^{14}C , chlorine, e.g., ^{36}Cl , fluorine, e.g., ^{18}F , iodine, e.g., ^{123}I and ^{125}I , nitrogen, e.g., ^{13}N and ^{15}N , oxygen, e.g., ^{15}O , ^{17}O and ^{18}O , and sulfur, e.g., ^{35}S . Isotopically-labeled forms of the thienotriazolodiazepine compounds generally can be prepared by conventional techniques known to those skilled in the art.

5 [00119] Certain isotopically-labeled forms of the compound of Formula (1), for example those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium (^3H) and carbon-14 (^{14}C) are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with heavier isotopes such as deuterium (^2H) may afford certain therapeutic advantages that result from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Substitution with positron emitting isotopes, such as ^{11}C , ^{18}F , ^{15}O , and ^{13}N can be used in Positron Emission Tomography (PET) studies for examining substrate receptor occupancy.

10 [00120] In some embodiments, the thienotriazolodiazepine compounds disclosed herein can exist in solvated as well as unsolvated forms with pharmaceutically acceptable solvents. It will be understood by those skilled-in the art that a solvate is a complex of variable stoichiometry formed by a solute (in this case, the thienotriazolodiazepine compounds described herein) and a solvent. It is preferred that such solvents not interfere with the biological activity of the solute (the thienotriazolodiazepine compounds). Examples of suitable solvents for solvate formation include, but are not limited to, water, methanol, dimethyl sulfoxide, ethanol and acetic acid. Suitably the solvent used is a pharmaceutically acceptable solvent. Suitably the solvent used is water. In one embodiment, pharmaceutically acceptable solvates of the thienotriazolodiazepine compounds, described herein, include ethanol solvate, a isopropanol solvate, a dioxolane solvate, a 25 tetrahydrofuran solvate, a dimethyl sulfoxide solvate, tert-butanol solvate, 2-butanol solvate, dioxolane solvate, 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (“DMPU”) solvate, 1,3-dimethylimidazolidinone (“DMI”) solvate, and 1,3-dimethylimidazolidinone (“DMP”) solvate, or mixtures thereof.

20 [00121] In some embodiments, the thienotriazolodiazepine compounds, described herein, may contain one or more chiral centers and/or double bonds and, therefore, may exist as geometric isomers, enantiomers or diastereomers. The enantiomer and diastereomers of the thienotriazolodiazepine compounds may be designated in accordance with the Cahn–Ingold–Prelog convention, which assigns an “R” or “S” descriptor to each stereocenter (also sometimes referred to

as a chiral center) and an *E* or *Z* descriptor to each carbon-carbon double bond (to designate geometric isomers) so that the configuration of the entire molecule can be specified uniquely by including the descriptors in its systematic name.

[00122] In some embodiments, the thienotriazolodiazepine compounds, described herein, may exist as a racemic mixture, or racemate, which includes equal amounts of left- and right-handed enantiomers of a chiral molecule. Such a racemic mixture may be denoted by the prefix (\pm) - or *dl*-, indicating an equal (1:1) mixture of dextro and levo isomers. Also, the prefix *rac*- (or *racem*-) or the symbols *RS* and *SR* may be used to designate the racemic mixture.

[00123] Geometric isomers, resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a cycloalkyl or heterocyclic ring, can also exist in the compounds of the present invention. In some embodiments, the symbol ---- may be used to denote a bond that may be a single, double or triple bond. Substituents around a carbon-carbon double bond are designated as being in the “*Z*” or “*E*” configuration wherein the terms “*Z*” and “*E*” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the “*E*” and “*Z*” isomers. Substituents around a carbon-carbon double bond alternatively can be referred to as “*cis*” or “*trans*,” where “*cis*” represents substituents on the same side of the double bond and “*trans*” represents substituents on opposite sides of the double bond. The arrangement of substituents around a carbocyclic ring can also be designated as “*cis*” or “*trans*.” The term “*cis*” represents substituents on the same side of the plane of the ring and the term “*trans*” represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of a plane of a ring are designated “*cis/trans*” or “*Z/E*.”

[00124] In some embodiments, thienotriazolodiazepine compounds disclosed herein may exist in single or multiple crystalline forms or polymorphs. In one embodiment, a thienotriazolodiazepine compound disclosed herein comprises an amorphous form thereof. In one embodiment, a thienotriazolodiazepine compound disclosed herein comprises a single polymorph thereof. In another embodiment, a thienotriazolodiazepine compound disclosed herein comprises a mixture of polymorphs thereof. In another embodiment, the compound is in a crystalline form.

[00125] In some embodiments, thienotriazolodiazepine compounds disclosed herein may exist as a single enantiomers or in enantiomerically enriched forms. In one embodiment, a thienotriazolodiazepine compound disclosed herein exists in an enantiomeric excess of more than 80%. In one embodiment, a thienotriazolodiazepine compound disclosed herein exists in an enantiomeric excess of more than 90%. In one embodiment, a thienotriazolodiazepine compound

disclosed herein exists in an enantiomeric excess of more than 98%. In one embodiment, a thienotriazolodiazepine compound disclosed herein exists in an enantiomeric excess of more than 99%. In some embodiments, a thienotriazolodiazepine compound disclosed herein exists in an enantiomeric excess selected from the group consisting of at least 10%, at least 25%, at least 50%, at 5 least 75%, at least 90%, at least 95%, at least 98%, at least and at least 99% enantiomeric excess.

[00126] For a pair of enantiomers, enantiomeric excess (ee) of enantiomer *E1* in relation to enantiomer *E2* can be calculated using the following equation eq. (1):


$$\% \text{ enantiomeric excess of } E1 = \frac{(E1 - E2) \times 100\%}{(E1 + E2)} \quad \text{eq. (1)}$$

Relative amounts of *E1* and *E2* can be determined by chiral high performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) or any other suitable methods. In 10 some embodiments, purity of an enantiomeric compound may refer to the amount of the enantiomers *E1* and *E2*, relative to the amount of other materials, which may notably include by-products and/or unreacted reactants or reagents.


[00127] In some embodiments, thienotriazolodiazepine compounds of Formula (1) include, but are not limited to, the thienotriazolodiazepine compounds (1-1) to (1-18), which are listed in the 15 following Table A.

[00128] Table A: Exemplary compounds which may be used in the formulations described herein:

(1-1)





(1-2)




(1-3)


(1-4)



(1-5)




(1-6)




[00129] Table A (continued):

(1-7)




(1-8)




(1-9)


(1-10)




(1-11)




(1-12)




(1-13)



(1-14)




(1-15)



(1-16)

[00130] Table A (continued):



[00131] In some embodiments, thienotriazolodiazepine compounds of Formula (1) include (i) (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof, (ii) methyl (S)-{4-(3'-cyanobiphenyl-4-yl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl}acetate, (iii) methyl (S)-{2,3,9-trimethyl-4-(4-phenylaminophenyl)-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl}acetate; and (iv) methyl (S)-{2,3,9-trimethyl-4-[4-(3-phenylpropionylamino)phenyl]-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl}acetate.

[00132] In some embodiments, thienotriazolodiazepine compounds of Formula (1) include (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide.

IV. Formulations:

[00133] The compound of Formula (1) presents highly specific difficulties in relation to administration generally and the preparation of galenic compositions in particular, including the particular problems of drug bioavailability and variability in inter- and intra-patient dose response, necessitating development of a non-conventional dosage form with respect to the practically water-insoluble properties of the compound.

[00134] Previously, it had been found that the compound of Formula (1) could be formulated as a solid dispersion with the carrier ethyl acrylate-methyl methacrylate-trimethylammonioethyl methacrylate chloride copolymer (Eudragit RS, manufactured by Rohm) to provide an oral formulation that preferentially released the pharmaceutical ingredient in the lower intestine for treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease (US Patent Application 20090012064 A1, published Jan 8, 2009). It was found, through various experiments, including animal tests, that in inflammatory bowel diseases drug release in a lesion and a direct action thereof on the inflammatory lesion were more important than the absorption of the drug into circulation from the gastrointestinal tract.

[00135] It has now been unexpectedly found that thienotriazolodiazepine compounds, according to Formula (1), pharmaceutically acceptable salts, solvates, including hydrates, racemates, enantiomers isomers, and isotopically-labeled forms thereof, can be formulated as a solid dispersion with pharmaceutically acceptable polymers to provide an oral formulation that provides high absorption of the pharmaceutical ingredient into the circulation from the gastrointestinal tract for treatment of diseases other than inflammatory bowel diseases. Studies in both dogs and humans have confirmed high oral bioavailability of these solid dispersions compared with the Eudragit solid dispersion formulation previously developed for the treatment of inflammatory bowel disease.

[00136] Solid dispersions are a strategy to improve the oral bioavailability of poorly water soluble drugs.

[00137] The term "solid dispersion" as used herein refers to a group of solid products including at least two different components, generally a hydrophilic carrier and a hydrophobic drug, the thienotriazolodiazepine compounds, according to Formula (1). Based on the drug's molecular arrangement within the dispersion, six different types of solid dispersions can be distinguished. Commonly, solid dispersions are classified as simple eutectic mixtures, solid solutions, glass solution and suspension, and amorphous precipitations in a crystalline carrier. Moreover, certain combinations can be encountered, for example, in the same sample some molecules may be present in clusters while some are molecularly dispersed.

[00138] In one embodiment, the thienotriazolodiazepine compounds, according to Formula (1) can be dispersed molecularly, in amorphous particles (clusters). In another embodiment, the thienotriazolodiazepine compounds, according to Formula (1) can be dispersed as crystalline particles. In one embodiment, the carrier can be crystalline. In another embodiment, the carrier can be amorphous.

[00139] In one embodiment, the present invention provides a pharmaceutical composition comprising a solid dispersion of a thienotriazolodiazepine compound, in accordance with Formula (1), or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof; and a pharmaceutically acceptable polymer. In 5 one embodiment, the pharmaceutically acceptable polymer is hypromellose acetate succinate (also called hydroxypropylmethylcellulose acetate succinate or HPMCAS). In one embodiment, the dispersion has a thienotriazolodiazepine compound to hydroxypropylmethylcellulose acetate succinate (HPMCAS) weight ratio of 1:3 to 1:1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In 10 another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 130 °C to 140 °C. In other such embodiments, the single Tg occurs at about 135 °C. In some such 15 embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). For the purpose of this application “substantially free” shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound of Formula (1).

20 [00140] In one embodiment, the present invention provides a pharmaceutical composition comprising a solid dispersion of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof in a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is polyvinylpyrrolidone (also called povidone 25 or PVP). In one embodiment, the dispersion has a thienotriazolodiazepine compound to PVP weight ratio of 1:3 to 1:1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition 30 temperature (Tg). In some embodiments, the single Tg occurs between 175 °C to about 185 °C. In other such embodiments, the single Tg occurs at about 179 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of

diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). For the purpose of this application “substantially free” shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound of Formula (1).

5 [00141] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of an amorphous form of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is hypromellose acetate succinate. In one 10 embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to hypromellose acetate succinate ranges from 1:3 to 1:1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the 15 glass transition temperature (Tg). In some embodiments, the single Tg occurs between 130 °C to 140 °C. In other such embodiments, the single Tg occurs at about 135 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound 20 of Formula (1). For the purpose of this application “substantially free” shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound of Formula (1).

[00142] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of an amorphous form of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is polyvinylpyrrolidone. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to polyvinylpyrrolidone ranges from 1:3 to 1:1. In one embodiment, at least some portion of the thienotriazolodiazepine compound 25 is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition 30 temperature (Tg). In some embodiments, the single Tg occurs between 175 °C to about 185 °C. In

other such embodiments, the single Tg occurs at about 179 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula 5 (1). For the purpose of this application “substantially free” shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound of Formula (1).

[00143] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of a crystalline form of a thienotriazolodiazepine compound of Formula (1) or a 10 pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is hypromellose acetate succinate. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to hypromellose acetate succinate ranges from 1:3 to 1:1.

[00144] In one embodiment, a pharmaceutical composition of the present invention comprises a 15 solid dispersion of a crystalline form of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is polyvinylpyrrolidone. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to polyvinylpyrrolidone ranges 20 from 1:3 to 1:1.

[00145] In some embodiments, a pharmaceutical composition comprising a solid dispersion is prepared by spray drying.

[00146] In one embodiment, a pharmaceutical composition of the present invention comprises a 25 spray dried solid dispersion of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is hypromellose acetate succinate. In one embodiment, the weight ratio of compound (1) to hypromellose acetate succinate ranges from 1:3 to 30 1:1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition

temperature (Tg). In some embodiments, the single Tg occurs between 130 °C to 140 °C. In other such embodiments, the single Tg occurs at about 135 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of 5 diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). For the purpose of this application “substantially free” shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound of Formula (1).

[00147] In one embodiment, a pharmaceutical composition of the present invention comprises a 10 spray dried solid dispersion of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is polyvinylpyrrolidone. In one embodiment, the weight ratio of compound (1) to polyvinylpyrrolidone ranges from 1:3 to 1:1. In one 15 embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 175 °C to 185 °C. In other such embodiments, the 20 single Tg occurs at about 179 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). For the purpose of this application “substantially free” shall mean the absence of a diffraction line, above the 25 amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound of Formula (1).

[00148] In one embodiment, a pharmaceutical composition of the present invention comprises a spray dried solid dispersion of an amorphous form of a thienotriazolodiazepine compound of 30 Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is hypromellose acetate succinate. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to hypromellose acetate succinate ranges from 1:3 to 1:1. In one embodiment, at least some portion

of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg 5 occurs between 130 °C to 140 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In other such embodiments, the single Tg occurs at about 135 °C. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). For the purpose of this application “substantially 10 free” shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound of Formula (1).


[00149] In one embodiment, a pharmaceutical composition of the present invention comprises a spray dried solid dispersion of an amorphous form of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an 15 enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is polyvinylpyrrolidone. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to polyvinylpyrrolidone ranges from 1:3 to 1:1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In 20 another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 175 °C to 185 °C. In other such embodiments, the single Tg occurs at about 179 °C. In some such 25 embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1). For the purpose of this application “substantially free” shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound of Formula (1).

[00150] In one embodiment, a pharmaceutical composition of the present invention comprises a spray dried solid dispersion of a crystalline form of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In

one embodiment, the pharmaceutically acceptable polymer is hypromellose acetate succinate. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to hypromellose acetate succinate ranges from 1:3 to 1:1.

[00151] In one embodiment, a pharmaceutical composition of the present invention comprises a spray dried solid dispersion of a crystalline form of a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is polyvinylpyrrolidone. In one embodiment, the weight ratio of thienotriazolodiazepine compound of Formula (1) to polyvinylpyrrolidone ranges from 1:3 to 1:1.

[00152] In one preferred embodiment, the present invention provides a pharmaceutical composition comprising a solid dispersion of 2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide dihydrate, compound (1-1):



or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is HPMCAS. In one embodiment, the dispersion has compound (1-1) and HPMCAS in a weight ratio of 1:3 to 1:1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In one embodiment, the solid dispersion is spray dried. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 130 °C to 140 °C. In other such embodiments, the single Tg occurs at about 135 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially

free of diffraction lines associated with crystalline thienotriazolodiazepine compound (1-1). For the purpose of this application “substantially free” shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound (1-1).

5 [00153] In another embodiment, the pharmaceutical composition comprises a solid dispersion compound (1-1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form; and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is PVP. In one embodiment, the dispersion has compound (1-1) and PVP in weight ratio 1:3 to 1:1. In one embodiment, at least 10 some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In one embodiment, the solid dispersion is spray dried. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 175 °C to 185 °C. In other 15 such embodiments, the single Tg occurs at about 179 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound (1-1). For the purpose of this application “substantially free” shall mean the absence of a diffraction line, above 20 the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound (1-1).

[00154] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of an amorphous form of a thienotriazolodiazepine compound (1-1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an 25 isomer, or an isotopically-labeled form thereof; and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is HPMCAS. In one embodiment, the dispersion has compound (1-1) and HPMCAS in a weight ratio of 1:3 to 1:1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is 30 homogeneously dispersed throughout the solid dispersion. In one embodiment, the solid dispersion is spray dried. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 130 °C to 140 °C. In other such embodiments, the single Tg occurs at about 135 °C. In some such embodiments, the

solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound (1-1). For the purpose of this application “substantially free” shall mean the absence of a diffraction line, above 5 the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound (1-1).

[00155] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of an amorphous form of a thienotriazolodiazepine compound (1-1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an 10 isomer, or an isotopically-labeled form thereof; and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is PVP. In one embodiment, the dispersion has compound (1-1) and PVP in weight ratio 1:3 to 1:1. In one embodiment, at least some portion of the thienotriazolodiazepine compound is homogeneously dispersed throughout the solid dispersion. In another embodiment, the thienotriazolodiazepine compound is homogeneously 15 dispersed throughout the solid dispersion. In one embodiment, the solid dispersion is spray dried. In some embodiments, the solid dispersion exhibits a single inflection for the glass transition temperature (Tg). In some embodiments, the single Tg occurs between 175 °C to 185 °C. In other such embodiments, the single Tg occurs at about 189 °C. In some such embodiments, the solid dispersion was exposed to a relative humidity of 75 % at 40 °C for at least one month. In some 20 embodiments, the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound (1-1). For the purpose of this application “substantially free” shall mean the absence of a diffraction line, above the amorphous halo, at about 21° 2-theta associated with crystalline thienotriazolodiazepine compound (1-1).

25 [00156] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of a crystalline form of a thienotriazolodiazepine compound (1-1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof; and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is HPMCAS. In one embodiment, the dispersion has compound (1-1) and HPMCAS in a weight ratio of 1:3 to 1:1. In one embodiment, 30 the solid dispersion is spray dried.

[00157] In one embodiment, a pharmaceutical composition of the present invention comprises a solid dispersion of a crystalline form of a thienotriazolodiazepine compound (1-1) or a

pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof; and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is PVP. In one embodiment, the dispersion has compound (1-1) and PVP in weight ratio 1:3 to 1:1. In one embodiment, the solid dispersion is spray dried.

5 [00158] The solid dispersions of the invention, described herein, exhibit especially advantageous properties when administered orally. Examples of advantageous properties of the solid dispersions include, but are not limited to, consistent and high level of bioavailability when administered in standard bioavailability trials in animals or humans. The solid dispersions of the invention can 10 include a solid dispersion comprising thienotriazolodiazepine compound of Formula (1) and a polymer and additives. In some embodiments, the solid dispersions can achieve absorption of the thienotriazolodiazepine compound of Formula (1) into the bloodstream that cannot be obtained by merely admixing the thienotriazolodiazepine compound of Formula (1) with additives since the thienotriazolodiazepine compound of Formula (1) drug has negligible solubility in water and most 15 aqueous media. The bioavailability, of thienotriazolodiazepine compound of Formula (1) or of thienotriazolodiazepine compound (1-1) may be measured using a variety of in vitro and/or in vivo studies. The in vivo studies may be performed, for example, using rats, dogs or humans.

20 [00159] The bioavailability may be measured by the area under the curve (AUC) value obtained by plotting a serum or plasma concentration, of the thienotriazolodiazepine compound of Formula (1) or thienotriazolodiazepine compound (1-1), along the ordinate (Y-axis) against time along the abscissa (X-axis). The AUC value of the thienotriazolodiazepine compound of Formula (1) or 25 thienotriazolodiazepine compound (1-1) from the solid dispersion, is then compared to the AUC value of an equivalent concentration of crystalline thienotriazolodiazepine compound of Formula (1) or crystalline thienotriazolodiazepine compound (1-1) without polymer. In some embodiments, the solid dispersion provides an area under the curve (AUC) value, when administered orally to a dog, 30 that is selected from: at least 0.4 times, 0.5 times, 0.6 time, 0.8 time, 1.0 times, a corresponding AUC value provided by a control composition administered intravenously to a dog, wherein the control composition comprises an equivalent quantity of a crystalline thienotriazolodiazepine compound of Formula (1).

30 [00160] The bioavailability may be measured by in vitro tests simulating the pH values of a gastric environment and an intestine environment. The measurements may be made by suspending a solid dispersion of the thienotriazolodiazepine compound of Formula (1) or thienotriazolodiazepine compound (1-1), in an aqueous in vitro test medium having a pH between 1.0 to 2.0, and the pH is

then adjusted to a pH between 5.0 and 7.0, in a control in vitro test medium. The concentration of the amorphous thienotriazolodiazepine compound of Formula (1) or amorphous thienotriazolodiazepine compound (1-1) may be measured at any time during the first two hours following the pH adjustment. In some embodiments, the solid dispersion provides a concentration, 5 of the amorphous thienotriazolodiazepine compound of Formula (1) or amorphous thienotriazolodiazepine compound (1-1), in an aqueous in vitro test medium at pH between 5.0 to 7.0 that is selected from: at least 5-fold greater, at least 6 fold greater, at least 7 fold greater, at least 8 fold greater, at least 9 fold greater or at least 10 fold greater, compared to a concentration of a crystalline thienotriazolodiazepine compound of Formula (1) or crystalline thienotriazolodiazepine 10 compound (1-1), without polymer.

[00161] In other embodiments, the concentration of the amorphous thienotriazolodiazepine compound of Formula (1) or amorphous thienotriazolodiazepine compound (1-1), from the solid dispersion placed in an aqueous in vitro test medium having a pH of 1.0 to 2.0, is: at least 40%, at least 50% higher, at least 60 %, at least 70 %; at least 80 %, than a concentration of a crystalline 15 thienotriazolodiazepine compound of Formula (1) without polymer. In some such embodiments, the polymer of the solid dispersion is HPMCAS. In some such embodiments, the polymer of the solid dispersion is PVP.

[00162] In other embodiments, a concentration of the amorphous thienotriazolodiazepine compound of Formula (1) or amorphous thienotriazolodiazepine compound (1-1), from the solid 20 dispersion, is: at least 40%, at least 50% higher, at least 60 %, at least 70 %; at least 80 %, compared to a concentration of thienotriazolodiazepine compound of Formula (1), from a solid dispersion of thienotriazolodiazepine compound of the Formula (1) and a pharmaceutically acceptable polymer selected from the group consisting of: hypromellose phthalate and ethyl acrylate-methyl 25 methacrylate-trimethylammonioethyl methacrylate chloride copolymer, wherein each solid dispersion was placed in an aqueous in vitro test medium having a pH of 1.0 to 2.0. In some such embodiments, the polymer of the solid dispersion is HPMCAS. In some such embodiments, the polymer of the solid dispersion is PVP.

[00163] In some embodiments, the solid dispersions, described herein, exhibit stability against 30 recrystallization of the thienotriazolodiazepine compound of the Formula (1) or the thienotriazolodiazepine compound (1-1) when exposed to humidity and temperature over time. In one embodiment, the concentration of the amorphous thienotriazolodiazepine compound of the Formula (1) or the thienotriazolodiazepine compound (1-1) which remains amorphous is selected

from: at least 90 %, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% and at least 99%.

V. Dosage Forms:

[00164] Suitable dosage forms that can be used with the solid dispersions of the present invention include, but are not limited to, capsules, tablets, mini-tablets, beads, beadlets, pellets, granules, granulates, and powder. Suitable dosage forms may be coated, for example using an enteric coating. Suitable coatings may comprise but are not limited to cellulose acetate phthalate, hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose phthalate, a polymethylacrylic acid copolymer, or hydroxylpropylmethylcellulose acetate succinate (HPMCAS).
In some embodiments, certain combinations can be encountered, for example, in the same sample some molecules of the thienotriazolodiazepine of the present invention may be present in clusters while some are molecularly dispersed with a carrier.

[00165] In some embodiments, the solid dispersions of the invention may be formulated as tablets, caplets, or capsules. In one some embodiments, the solid dispersions of the invention may be formulated as mini-tablets or pour-into-mouth granules, or oral powders for constitution. In some embodiments, the solid dispersions of the invention are dispersed in a suitable diluent in combination with other excipients (e.g., re-crystallization/precipitation inhibiting polymers, taste-masking components, etc.) to give a ready-to-use suspension formulation. In some embodiments, the solid dispersions of the invention may be formulated for pediatric treatment.

[00166] In one embodiment, the pharmaceutical composition of the present invention is formulated for oral administration. In one embodiment, the pharmaceutical composition comprises a solid dispersion, according to the various embodiments described herein, comprising a thienotriazolodiazepine compound of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof; and a polymer carrier. In one embodiment, the pharmaceutical composition further includes one or more additives such as disintegrants, lubricants, glidants, binders, and fillers.

[00167] Examples of suitable pharmaceutically acceptable lubricants and pharmaceutically acceptable glidants for use with the pharmaceutical composition include, but are not limited to, colloidal silica, magnesium trisilicate, starches, talc, tribasic calcium phosphate, magnesium stearate, aluminum stearate, calcium stearate, magnesium carbonate, magnesium oxide, polyethylene

glycol, powdered cellulose, glycetyl behenate, stearic acid, hydrogenated castor oil, glycetyl monostearate, and sodium stearyl fumarate.

[00168] Examples of suitable pharmaceutically acceptable binders for use with the pharmaceutical composition include, but are not limited to starches; celluloses and derivatives thereof, e.g.,

5 microcrystalline cellulose (e.g., AVICEL PH from FMC), hydroxypropyl cellulose, hydroxyethyl cellulose, and hydroxylpropylmethylcellulose (HPMC, e.g., METHOCEL from Dow Chemical); sucrose, dextrose, corn syrup; polysaccharides; and gelatin.

[00169] Examples of suitable pharmaceutically acceptable fillers and pharmaceutically acceptable diluents for use with the pharmaceutical composition include, but are not limited to, confectioner's sugar, compressible sugar, dextrates, dextrin, dextrose, lactose, mannitol, microcrystalline cellulose (MCC), powdered cellulose, sorbitol, sucrose, and talc.

[00170] In some embodiments, excipients may serve more than one function in the pharmaceutical composition. For example, fillers or binders may also be disintegrants, glidants, anti-adherents, lubricants, sweeteners and the like.

15 [00171] In some embodiments, the pharmaceutical compositions of the present invention may further include additives or ingredients, such as antioxidants (e.g., ascorbyl palmitate, butylated hydroxylanisole (BHA), butylated hydroxytoluene (BHT), α -tocopherols, propyl gallate, and fumaric acid), antimicrobial agents, enzyme inhibitors, stabilizers (e.g., malonic acid), and/or preserving agents.

20 [00172] Generally, the pharmaceutical compositions of the present invention may be formulated into any suitable solid dosage form. In some embodiments, the solid dispersions of the invention are compounded in unit dosage form, e.g., as a capsule, or tablet, or a multi-particulate system such as granules or granulates or a powder, for administration.

25 [00173] In one embodiment, a pharmaceutical compositions includes a solid dispersion of a thienotriazolodiazepine compound of Formula (1), according to the various embodiments of solid dispersions described herein, and hydroxypropylmethylcellulose acetate succinate (HPMCAS), wherein the thienotriazolodiazepine compound is amorphous in the solid dispersion and has a thienotriazolodiazepine compound to hydroxypropylmethylcellulose acetate succinate (HPMCAS), weight ratio of 1:3 to 1:1; 45 -50 wt. % of lactose monohydrate; 35-40 wt. % of microcrystalline cellulose; 4-6 wt. % of croscarmellose sodium; 0.8-1.5 wt. % of colloidal silicon dioxide; and 0.8-1.5 wt. % of magnesium stearate.

VI. Dosage:

[00174] In one embodiment, the present invention provides a pharmaceutical composition that maybe formulated into any suitable solid dosage form. In one embodiment, a pharmaceutical composition in accordance with the present invention comprises one or more of the various embodiments of the thienotriazolodiazepine of Formula (1) as described herein in a dosage amount ranging from about 10 mg to about 100 mg. In one embodiment, the pharmaceutical composition of the present invention includes one or more of the various embodiments of the thienotriazolodiazepine of Formula (1) as described herein in a dosage amount selected from the group consisting of from about 10 mg to about 100 mg, about 10 mg to about 90 mg, about 10 mg to about 80 mg, about 10 mg to about 70 mg, about 10 mg to about 60 mg, about 10 mg to about 50 mg, about 10 mg to about 40 mg, about 10 mg to about 30 mg, and about 10 mg to about 20 mg. In one embodiment, the pharmaceutical composition of the present invention includes one or more of the various embodiments of the thienotriazolodiazepine of Formula (1) as described herein in a dosage amount selected from the group consisting of about 10 mg, about 50 mg, about 75 mg, about 100 mg.

[00175] In one embodiment, the pharmaceutical composition of the present invention includes administering to a subject in need thereof one or more of the various embodiments of the thienotriazolodiazepine of Formula (I) as described herein in a dosage amount selected from the group consisting of about 1 mg, about 2 mg, about 2.5 mg, about 3 mg, about 4 mg, about 5 mg, about 7.5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, and about 150 mg, and in a dosage form selected from the group consisting of once weekly, once daily every sixth day, once daily every fifth day, once daily every fourth day, once daily every third day, once daily every other day, once daily, twice daily, three times daily, four times daily, and five times daily. In another embodiment, any of the foregoing dosage amounts or dosage forms is decreased periodically or increased periodically. In one embodiment, the pharmaceutical composition of the present invention includes administering to a subject in need thereof a thienotriazolodiazepine selected from the group consisting of compounds (1-1), (1-2), (1-3), (1-4), (1-5), (1-6), (1-7), (1-8), (1-9), (1-10), (1-11), (1-12), (1-13), (1-14), (1-15), (1-16), (1-17), and (1-18), in a dosage amount selected from the group consisting of about 1 mg, about 2 mg, about 2.5 mg, about 3 mg, about 4 mg, about 5 mg, about 7.5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50

mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, and about 150 mg, and in a dosage form selected from the group consisting of once weekly, once daily every sixth day, once daily every fifth day, once daily every fourth day, once daily every 5 third day, once daily every other day, once daily, twice daily, three times daily, four times daily, and five times daily. In another embodiment, any of the foregoing dosage amounts or dosage forms is decreased periodically or increased periodically.

[00176] Such unit dosage forms are suitable for administration 1 to 5 times daily depending on the particular purpose of therapy, the phase of therapy, and the like. In one embodiment, the dosage 10 form may be administered to a subject in need thereof at least once daily for at least two successive days. In one embodiment, the dosage form may be administered to a subject in need thereof at least once daily on alternative days. In one embodiment, the dosage form may be administered to a subject in need thereof at least weekly and divided into equal and/or unequal doses. In one embodiment, the dosage form may be administered to a subject in need thereof weekly, given either 15 on three alternate days and/or 6 times per week. In one embodiment, the dosage form may be administered to a subject in need thereof in divided doses on alternate days, every third day, every fourth day, every fifth day, every sixth day and/or weekly. In one embodiment, the dosage form may be administered to a subject in need thereof two or more equally or unequally divided doses per month.

20 [00177] The dosage form used, e.g., in a capsule, tablet, mini-tablet, beads, beadlets, pellets, granules, granulates, or powder may be coated, for example using an enteric coating. Suitable coatings may comprise but are not limited to cellulose acetate phthalate, hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose phthalate, a polymethylacrylic acid copolymer, or hydroxylpropylmethylcellulose acetate succinate (HPMCAS).

25 **VII. Process:**

[00178] The thienotriazolodiazepine compounds disclosed herein can exist as free base or as acid addition salt can be obtained according to the procedures described in US Patent Application Publication No. 2010/0286127, incorporated by reference in its entirety herein, or in the present 30 application. Individual enantiomers and diastereomers of the thienotriazolodiazepine compounds of the present invention can be prepared synthetically from commercially available starting materials

that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the 5 optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, (3) direct separation of the mixture of optical enantiomers on chiral liquid chromatographic columns or (4) kinetic resolution using stereoselective chemical or enzymatic reagents. Racemic mixtures can also be resolved into their component enantiomers by well-known methods, such as chiral-phase gas chromatography or crystallizing the compound in a chiral solvent.

10 **[00179]** If desired, a particular enantiomer of the thienotriazolodiazepine compounds disclosed herein may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an 15 appropriate optically-active acid or base, followed by resolution of the diastereomers, thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers. Various methods well known in the art may be used to to prepare the thienotriazolodiazepine compounds of Formula (1) with an enantiomeric excess of generally more than about 80%. Advantageously, preferred enantiomeric excess is of more than 80%, 20 preferably of more than 90%, more preferably of more than 95%, and most preferably of 99% and more.

[00180] The solid dispersions of the present invention can be prepared by a number of methods, including by melting and solvent evaporation. The solid dispersions of the present invention can also be prepared according to the procedures described in: Chiou WL, Riegelman S: 25 "Pharmaceutical applications of solid dispersion systems", *J. Pharm. Sci.* 1971; 60:1281-1302; Serajuddin ATM: "Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recentbreakthroughs", *J. Pharm. Sci.* 1999; 88:1058-1066; Leuner C, Dressman J: "Improving drug solubility for oral delivery using solid dispersions", *Eur. J. Pharm. Biopharm.* 2000; 50:47-60; and Vasconcelos T, Sarmento B, Costa P: "Solid dispersions as strategy to improve 30 oral bioavailability of poor water soluble drugs", *Drug Discovery Today* 2007; 12:1068-1075, all of which are incorporated herein by reference in their entireties.

[00181] In one embodiment, solid dispersions of the present invention are prepared by a melting process. In one embodiment, the melting process comprises melting one or more of the various embodiments of the thienotriazolodiazepine of Formula (1) within a carrier. In one embodiment, the melting process includes cooling a melted compound of the present invention and a carrier. In one embodiment, the melting process comprises pulverization of the melted compound and the carrier. In one embodiment, a melted compound of the present invention and a carrier are pulverized following the cooling step.

[00182] In some embodiments in which the thienotriazolodiazepine of Formula (1) or a pharmaceutically acceptable salt, a solvate, including a hydrate, a racemate, an enantiomer, an isomer, or an isotopically-labeled form thereof and the carrier are incompatible, a surfactant may be added during the melting step to prevent formation of two liquid phases or a suspension in the heated mixture. In some embodiments, one or more of the various embodiments of the thienotriazolodiazepine of Formula (1) is suspended in a previously melted carrier, instead of using both drug and carrier in the melted state, thereby reducing the process temperature. In one embodiment, melted drug and carrier mixture is cooled an ice bath agitation. In one embodiment, melted drug and carrier mixture is cooled and solidified by spray cooling (alternatively spray congealing).

[00183] In one embodiment, melted drug and carrier mixture is cooled and solidified by forming the melt into particles by spraying the melt into a cooling chamber through which ambient or cooled, low temperature air is passing. In one embodiment, melted drug and carrier mixture is cooled and solidified by atomization and re-solidification of the molten dispersion in a suitable fluid bed processor. In one embodiment, melted drug and carrier mixture is cooled and solidified by melt-granulation in a heatable high-shear mixer.

[00184] In some embodiments, hot-stage extrusion or melt agglomeration may be used to avoid melting limitations of the drug. Hot-stage extrusion consists of the extrusion, at high rotational speed, of the drug and carrier, previously mixed, at melting temperature for a short period of time; the resulting product is collected after cooling at room temperature and milled.

[00185] In one embodiment, one or more of the various embodiments of the thienotriazolodiazepine of Formula (1) is processed at a reduced processing temperature to avoid degradation of any thermally labile compound. In one embodiment, the reduced processing

temperature is achieved by associating a hot-stage extrusion with a temporary plasticizer such as carbon dioxide. In one embodiment, melt agglomeration is used in the preparation of solid dispersions in accordance with the present invention in conventional high shear mixers or in a rotary processors. In one embodiment, the solid dispersion in accordance with the present invention is 5 prepared by adding a molten carrier containing a thienotriazolodiazepine compound in accordance with the present invention to a heated excipient. In one embodiment, the solid dispersion in accordance with the present invention is prepared by adding by adding a molten carrier to a heated mixture of the thienotriazolodiazepine in accordance with the present invention and one or more excipients. In one embodiment, the solid dispersion in accordance with the present invention is 10 prepared by heating a mixture of a thienotriazolodiazepine compound in accordance with the present invention, a carrier and one or more excipients to a temperature within or above the melting range of the carrier.

[00186] In some embodiments, a one or more of the various embodiments for the formulation of the thienotriazolodiazepine, according to Formula (1), is prepared by a solvent evaporation method. 15 In one embodiment, the solvent evaporation method comprises solubilization of a thienotriazolodiazepine compound, according to Formula (1), carrier in a volatile solvent that is subsequently evaporated. In one embodiment, the volatile solvent may one or more excipients. In one embodiment, the one or more excipients include, but are not limited to anti-sticking agents, inert fillers, surfactants wetting agents, pH modifiers and additives. In one embodiment, the excipients 20 may dissolved or in suspended or swollen state in the volatile solvent.

[00187] In one embodiment, preparation of solid dispersions in accordance with the present invention includes drying one or more excipients suspended in a volatile solvent. In one embodiment, the drying includes vacuum drying, slow evaporation of the volatile solvent at low temperature, use of a rotary evaporator, spray-drying, spray granulation, freeze-drying, or use of 25 supercritical fluids.

[00188] In one embodiment, spray drying preparation of a formulation for the thienotriazolodiazepine composition, according to Formula (1), is used which involves atomization of a suspension or a solution of the composition into small droplets, followed by rapid removal solvent from the formulation. In one embodiment, preparation of a formulation in accordance with 30 the present invention involves spray granulation in which a solution or a suspension of the composition in a solvent is sprayed onto a suitable chemically and/or physically inert filler, such as

lactose or mannitol. In one embodiment, spray granulation of the solution or the suspension of the composition is achieved via two-way or three-way nozzles.

5 [00189] In some embodiments, preparation of solid dispersions in accordance with the present invention includes use of supercritical fluids. The term “supercritical fluids” refers to substances existing as a single fluid phase above their critical temperature and critical pressure. In one embodiment, preparation of a formulation, in accordance with the present invention, includes use a supercritical carbon dioxide fluid. In one embodiment, preparation of a formulation, in accordance with the present invention, using the supercritical fluid technique comprises dissolving a thienotriazolodiazepine compound, according to Formula (1), and carrier in a common solvent that 10 is introduced into a particle formation vessel through a nozzle, simultaneously with carbon dioxide; and spraying the solution to allow the solvent be rapidly extracted by the supercritical fluid, thereby resulting in the precipitation of solid dispersion particles on the walls of the vessel.

15 [00190] In some embodiments, preparation of solid dispersions in accordance with the present invention includes use of a co-precipitation method. In one embodiment, a non-solvent is added dropwise to a thienotriazolodiazepine composition, according to Formula (1), and a carrier solution, under constant stirring. In one embodiment, the thienotriazolodiazepine composition, according to Formula (1), and the carrier are co-precipitated to form microparticles during the addition of the non-solvent. In one embodiment, the resulting microparticles are filtered and dried to provide the desired solid dispersion.

20 [00191] The proportion of compound of Formula (1) and polymeric carrier(s) to be mixed is not particularly limited, as long as it can improve the bioavailability of the compound of Formula (1) and varies depending on the kind of polymer.

[00192] The invention is illustrated in the following non-limiting examples.

VIII. Examples:

25 [00193] The invention is illustrated in the following non-limiting examples.

Example 1: in vitro screening of solid dispersions of compound (1-1)

30 [00194] Ten solid dispersions were prepared using compound (1-1) and one of five polymers, including hypromellose acetate succinate (HPMCAS-M), hypromellose phthalate (HPMCP-HP55), polyvinylpyrrolidone (PVP), PVP-vinyl acetate (PVP-VA), and Euragit L100-55, at both 25% and 50% of compound (1-1) loading, for each polymer. Solid dispersions were prepared by a solvent

evaporation method, using spray-drying followed by secondary drying in a low-temperature convection oven. The performance of each solid dispersion was assessed via a non-sink dissolution performance test which measured both the total amount of drug and the amount of free drug present in solution over time. Non-sink dissolution was chosen because it best represents the *in vivo* situation for low soluble compounds. This test included a “gastric transfer” of dispersion from gastric pH (0.1N NaCl, pH 1.0) to intestinal pH (FaFSSIF, pH 6.5) approximately 30 to 40 minutes after the introduction of dispersion to the test medium, simulating *in vivo* conditions. [FaFSSIF is Fasted State Simulated Intestinal Fluid, comprised of 3 mM sodium taurocholate, 0.75 mM lechithin, 0.174 g NaOH pellets, 1.977 g NaH₂PO₄•H₂O, 3.093 g NaCl, and purified water qs 500 mL.] The amount of dissolved drug was quantified using a high-performance liquid chromatography (HPLC) method and an Agilent 1100 series HPLC. The dissolution profiles of the formulations (Figures 1A-1J) showed large increases in drug solubility in all dispersion candidates relative to the unformulated compound in the same media. Of the solid dispersions, the 25% compound (1-1) in PVP, 25% compound (1-1) in HPMCAS-M, and 50% compound (1-1) in HPMCAS-M dispersions provided enhanced oral absorption as compared to the unformulated compound, based on finding higher levels of free drug released at intestinal pH.

Example 2: *in vivo* screening of solid dispersions of compound (1-1)

[00195] The solid dispersions of compound (1-1), namely the 25% compound (1-1) in PVP, 25% compound (1-1) in HPMCAS-MG, and 50% compound (1-1) in HPMCAS-M dispersions, were prepared at larger scale for *in vivo* studies. Each formulation was assessed in the *in vitro* dissolution test described in Example 1. To ensure that these dispersions were both amorphous and homogeneous, each dispersion was assessed by powder x-ray diffraction (PXRD) and modulated differential scanning calorimetry (mDSC). The x-ray diffractometer was a Bruker D-2 Phaser. Additionally, to understand the effect of water on the glass transition temperature (T_g) for each dispersion, mDSC was performed on samples first equilibrated at a set relative humidity (i.e., 25%, 50%, and 75% RH) for at least 18 hours. [Water can act as a plasticizer for solid dispersions and the hygroscopicity of the system due to the active compound or polymer can affect the amount of water uptake by these systems.]

[00196] The non-sink dissolution results (Figures 2A-2C) were comparable to those found for the dispersions in Example 1. PXRD results (Figure 3) showed no evidence of crystalline compound in any of the dispersions and mDSC results (Figures 4A-4C) showed a single glass transition temperature (T_g) for each dispersion, indicating that each dispersion was homogeneous. An inverse

relationship between Tg and relative humidity was observed for each (Figure 5). Notably, for the 25% compound (1-1) in PVP solid dispersion equilibrated at 75% RH, there appeared to be two Tgs, indicating that phase separation was occurring, and this dispersion also showed a melt event at 75% RH, suggesting that crystallization occurred during the RH equilibration (Figure 6). This finding 5 suggests that the 25% compound (1-1) in PVP dispersion may be less stable than the HPMCAS-M dispersions.

[00197] To assess the bioavailability of the three dispersions, groups of male beagle dogs (three per group) were given a 3 mg/kg dose of an aqueous suspension of solid dispersion of compound (1-1) administered by oral gavage or a 1 mg/kg dose of compound (1-1) dissolved in 10 water:ethanol:polyethylene glycol (PEG) 400 (60:20:20) and administered as an intravenous bolus into the cephalic vein. Blood samples were collected from the jugular vein of each animal at 0 (pre-dose), 5, 15, and 30 minutes and 1, 2, 4, 8, 12, and 24 hours following intravenous administration and at 0 (pre-dose), 15 and 30 minutes and 1, 2, 4, 8, 12, and 24 hours following oral gavage 15 administration. The amount of compound (1-1) present in each sample was detected using a qualified LC-MS/MS method with a lower limit of quantification of 0.5 ng/mL. The area under the plasma concentration-time curve (AUC) was determined by use of the linear trapezoidal rule up to the last measurable concentration without extrapolation of the terminal elimination phase to infinity. The elimination half-life ($t_{1/2}$) was calculated by least-squares regression analysis of the terminal 20 linear part of the log concentration-time curve. The maximum plasma concentration (C_{max}) and the time to C_{max} (t_{max}) were derived directly from the plasma concentration data. The oral bioavailability (F) was calculated by dividing the dose normalized AUC after oral administration by the dose normalized AUC after intravenous administration and reported as percentages (%). 25 Results, summarized in Table 1 below, gave mean oral bioavailabilities of the 25% compound (1-1) in PVP, 25% compound (1-1) in HPMCAS-M, and 50% compound (1-1) in HPMCAS-M solid dispersions of 58%, 49%, and 74%, respectively.

Table 1: pharmacokinetic parameters of compound (1-1) after oral (po) and intravenous (iv) administrations to dogs (the values are averages from three dogs)

Compound (1-1) formulation	Dose & Route	C_{max} (ng/L)	t_{max} (hr)	AUC (ng•min/mL)	$t_{1/2}$ (hr)	F (%)
Solution in water:ethanol:PEG400 (60:20:20)	1 mg/kg IV	769	0.083	53,312	1.5	----
Aqueous suspension of 25% compound (1-1)/PVP solid dispersion	3 mg/kg PO	487	1.0	93,271	1.6	58
Aqueous suspension of 25%	3 mg/kg	228	0.5	78,595	2.0	49

compound (1-1)/HPMCAS-M solid dispersion	PO					
Aqueous suspension of 50% compound (1-1)/HPMCAS-M solid dispersion	3 mg/kg PO	371	1.0	118,174	1.5	74

AUC: area under the plasma concentration-time curve; C_{\max} : maximum plasma concentration; F: bioavailability; HPMCAS: hypromellose acetate sodium; IV: intravenous; PEG: polyethylene glycon; PO; *per os*, oral; PVP: polyvinylpyrrolidone; t_{\max} : time of C_{\max} ; $t_{1/2}$: plasma elimination half-life

5

Example 3: preparation and clinical use of capsules containing a solid dispersion of compound (1-1)

[00198] A gelatin capsule of 10 mg strength was prepared for initial clinical studies in patients with hematologic malignancies. Based on results of *in vitro* and *in vivo* testing of solid dispersions of compound (1-1), as described in Examples 1 and 2, a 50% compound (1-1) in HPMCAS-M solid dispersion was selected for capsule development. Capsule development was initiated targeting a fill weight of 190 mg in a size 3 hard gelatin capsule, as this configuration would potentially allow increasing the capsule strength by filling a larger size capsule while maintaining the pharmaceutical composition. Based on experience, four capsule formulations were designed with different amounts of disintegrant and with and without wetting agent. Since all four formulations showed similar disintegration test and dissolution test results, the simplest formulation (without wetting agent and minimum disintegrant) was selected for manufacturing. Manufacturing process development and scale-up studies were performed to confirm the spray drying process and post-drying times for the solid dispersion; blending parameters; roller compaction and milling of the blend to achieve target bulk density of approximately 0.60 g/cc; and capsule filling conditions.

[00199] Crystalline compound (1-1) and the polymer hypromellose acetate succinate (HPMCAS-M) were dissolved in acetone and spray-dried to produce solid dispersion intermediate (SDI) granules containing a 50% compound (1-1) loading. The SDI was shown by PXRD analysis to be amorphous and by mDSC analysis to be homogeneous (i.e., single Tg under ambient conditions). The 50% compound (1-1) in HPMCAS-M solid dispersion (1000 g) and excipients, including microcrystalline cellulose filler-binder (4428 g), croscarmellose sodium disintegrant (636 g), colloidal silicon dioxide dispersant/lubricant (156 g), magnesium stearate dispersant/lubricant (156 g), and lactose monohydrate filler (5364 g) were blended in stages in a V-blender. The blend was then compacted and granulated to obtain a bulk density of approximately 0.6 g/mL. The blend was dispensed into size 3 hard gelatin capsules (target fill weight: 190 mg) using an automated filling machine and finished capsules were polished using a capsule polisher machine.

[00200] Pharmacokinetic assessments were performed following oral dosing of 10 mg capsules containing the 50% compound (1-1) in HPMCAS solid dispersion and results were compared with pharmacokinetic assessments performed following oral dosing of administration of 4 x 10 mg capsules containing the Eudragit solid dispersion of compound (1-1) to healthy volunteers

5 [00201] A comparison of the two pharmaceutical compositions is provided in Tables 2A and 2B below. The Eudragit formulation previously was described in Example 5 in US Patent Application 2009/0012064 A1, published January 8, 2009. That application noted that the Eudragit solid dispersion formulation was made by dissolving and/or dispersing the thienotriazolodiazepine of formula (A) and coating excipients, including ammonio methacrylate copolymer type B (Eudragit 10 RS), methacrylic acid copolymer type C (Eudragit L100-55), talc, and magnesium aluminosilicate, in a mixture of water and ethanol. This heterogeneous mixture then was applied to microcrystalline cellulose spheres (Nonpareil 101, Freund) using a centrifugal fluidizing bed granulator to produce granules that were dispensed into size 2 hydroxypropyl methylcellulose capsules.

15 [00202] In both clinical studies, blood levels of compound (1-1) were determined using validated LC-MS/MS methods and pharmacokinetic analyses were performed based on plasma concentrations of compound (1-1) measured at various time points over 24 hours after capsule administration. Results, summarized in Table 3 below, showed that the HPMCAS-M solid dispersion formulation had over 3-fold higher bioavailability in humans than the Eudragit solid dispersion formulation based on AUCs (924*4 / 1140, adjusting for difference in doses administered). Additionally, based 20 on the observed T_{max} , the HPMCAS formulation is more rapidly absorbed than the Eudragit formulation (T_{max} of 1 h vs 4-6 h). The marked improvement in systemic exposure with the HPMCAS-M solid dispersion formulation is unexpected.

Table 2A: solid dispersion capsules of compound (1-1) for clinical use

pharmaceutical composition containing 50% HPMCAS solid dispersion of compound (1-1):
25 10 mg strength, size 3 hard gelatin capsule

Ingredient	Function	Capsule Content	
		mg	Wt %
Compound of formula (II)	active agent	10.0*	5.56
Hypromellose acetate succinate (HPMCAS-M)	carrier for solid dispersion	10.0	5.56
Lactose monohydrate	filler	85.0	47.22
Microcrystalline cellulose	filler-binder	70.0	38.89
Croscarmellose sodium	disintegrant	10.0	5.56
Collidal silicon dioxide	dispersant/lubricant	2.5	1.39
Magnesium stearate	dispersant/lubricant		
	Total	190.0	100.0

Table 2B: pharmaceutical composition containing Eudragit L100-55 solid dispersion of compound (1-1): 10 mg strength, size 2 hard gelatin capsule

Ingredient	Function	Capsule Content	
		mg	Wt %
Compound (1-1)	active agent	10.0*	3.8
Core:			
Microcrystalline cellulose spheres (Nonpareil 101, Freund, Inc)	vehicle	100.0	38.5
Compound/polymer layer:			
Ammonio methacrylate copolymer, type B (NF. PhEur) (Eudragit RS, Evonik)	coating agent	10.8	4.2
Methacrylic acid copolymer, type C (NF)/ Methacrylic acid-ethyl acrylate copolymer (1:1) type A (PhEur) (Eudragit L100-55, Evonik)	coating agent	25.2	9.7
Talc	coating agent	88.2	33.9
Magnesium aluminometasilicate (Neuslin, Fuji Chemical)	coating agent	20.0	7.7
Triethyl citrate	plasticizer	5.0	1.9
Silicon dioxide	fluidizing agent	0.8	0.3
		260.0	100.0

* as anhydrite

5

Table 3: pharmacokinetic parameters following oral administration of solid dispersions of compound (1-1) to humans

Compound (1-1) formulation	# Patients	Dose and Route	C _{max} (ng/mL)	T _{max} (hr)	AUC _{0-24h} (ng·h/mL)
Eudragit solid dispersion formulation	7	40 mg PO	83	4 to 6	1140
50% HPMCAS-M solid dispersion formulation	7	10 mg PO	286	1	925

AUC_{0-24h}: area under the OTX015 plasma concentration vs. time curve over 24 hours10 C_{max}: maximum concentration in plasma

hr: hour

HPMCAS: hypromellose acetate succinate

mL: milliliter

ng: nanogram

15 PO: *per os*, oralT_{max}: time of C_{max}[00203] Example 4. Oral exposure in the rat

[00204] The oral bioavailability of three formulations of solid dispersions of compound (1-1) was 20 determined in rats. The three dispersions chosen were the 25% dispersion of compound (1-1) in PVP, the 25% dispersion of compound (1-1) in HPMCAS-MG, and the 50% dispersion of compound (1-1) in HPMCAS-MG. The animals used in the study were Specific Pathogen Free

(SPF) Hsd:Sprague Dawley rats obtained from the Central Animal Laboratory at the University of Turku, Finland. The rats were originally purchased from Harlan, The Netherlands. The rats were female and were ten weeks of age, and 12 rats were used in the study. The animals were housed in polycarbonate Makrolon II cages (three animals per cage), the animal room temperature was 21 +/- 5 °C, the animal room relative humidity was 55 +/- 15%, and the animal room lighting was artificial and was cycled for 12 hour light and dark periods (with the dark period between 18:00 and 06:00 hours). Aspen chips (Tapvei Oy, Estonia) were used for bedding, and bedding was changed at least once per week. Food and water was provided prior to dosing the animals but was removed during the first two hours after dosing.

[00205] The oral dosing solutions containing the 25% dispersion of compound (1-1) in PVP, the 25% dispersion of compound (1-1) in HPMCAS-MG, and the 50% dispersion of compound (1-1) in HPMCAS-MG were prepared by adding a pre-calculated amount of sterile water for injection to containers holding the dispersion using appropriate quantities to obtain a concentration of 0.75 mg/mL of compound (1-1). The oral dosing solutions were subjected to vortex mixing for 20 seconds prior to each dose. The dosing solution for intravenous administration contained 0.25 mg/mL of compound (1-1) and was prepared by dissolving 5 mg of compound (1-1) in a mixture containing 4 mL of polyethylene glycol with an average molecular weight of 400 Da (PEG400), 4 mL of ethanol (96% purity), and 12 mL of sterile water for injection. The dosing solution containing the 25% dispersion of compound (1-1) in PVP was used within 30 minutes after the addition of water. The dosing solutions containing the 25% dispersion of compound (1-1) in HPMCAS-MG and the 50% dispersion of compound (1-1) in HPMCAS-MG were used within 60 minutes of after the addition of water. A dosing volume of 4 mL/kg was used to give dose levels of compound (1-1) of 1 mg/kg for intravenous administration and 3 mg/kg for oral administration. The dosing scheme is given in Table 4.

[00206] Table 4. Dosing scheme for rat oral exposure study.

Rat	Weight	Dose (mL)	Test Item	Route
1	236.5	0.95	Compound (1-1)	intravenous
2	221	0.88	Compound (1-1)	intravenous
3	237.5	0.95	Compound (1-1)	intravenous
4	255.5	1.02	25% dispersion of compound (1-1) in PVP	oral

5	224.2	0.90	25% dispersion of compound (1-1) in PVP	oral
6	219.2	0.88	25% dispersion of compound (1-1) in PVP	oral
7	251.6	1.01	25% dispersion of compound (1-1) in HPMCAS-MG	oral
8	240.4	0.96	25% dispersion of compound (1-1) in HPMCAS-MG	oral
9	238	0.95	25% dispersion of compound (1-1) in HPMCAS-MG	oral
10	226.6	0.91	50% dispersion of compound (1-1) in HPMCAS-MG	oral
11	228.4	0.91	50% dispersion of compound (1-1) in HPMCAS-MG	oral
12	228.5	0.91	50% dispersion of compound (1-1) in HPMCAS-MG	oral

[00207] Blood samples of approximately 50 μ L were collected into Eppendorf tubes containing 5 μ L of ethylenediaminetetraacetic acid (EDTA) solution at time points of 0.25, 0.5, 1, 2, 4, 8, 12, and 24 hours after dosing, with each sample collected within a window of 5 minutes from the prescribed 5 time point. From each sample, 20 μ L of plasma was obtained and stored at dry ice temperatures for analysis. Analysis of each sample for the concentration of compound (1-1) was performed using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantitation of 0.5 ng/mL.

[00208] Pharmacokinetic parameters were calculated with the Phoenix WinNonlin software 10 package (version 6.2.1, Pharsight Corp., CA, USA) with standard noncompartmental methods. The elimination phase half-life ($t_{1/2}$) was calculated by least-squares regression analysis of the terminal linear part of the log concentration-time curve. The area under the plasma concentration-time curve (AUC) was determined by use of the linear trapezoidal rule up to the last measurable concentration and thereafter by extrapolation of the terminal elimination phase to infinity. The mean residence 15 time (MRT), representing the average amount of time a compound remains in a compartment or system, was calculated by extrapolating the drug concentration profile to infinity. The maximum plasma concentration (C_{max}) and the time to C_{max} (t_{max}) were derived directly from the plasma concentration data. The tentative oral bioavailability (F) was calculated by dividing the dose normalised AUC after oral administration by the dose normalised AUC after intravenous

administration, i.e. $F = (AUC(\text{oral})/\text{Dose}(\text{oral}))/(\text{AUC}(\text{intravenous}) / \text{Dose}(\text{intravenous}))$ and is reported as percentage (%).

[00209] The pharmacokinetic parameters are given in Table 5, and the plasma concentration versus time plots are shown in Figures 7 and 8.

5 Table 5. Pharmacokinetic parameters of compound (1-1) after oral and intravenous administrations. The values are an average from three animals.

Compound	Parameter	1 mg/kg intravenous	3 mg/kg oral	F(%)
Compound (1-1) water:ethanol:PEG 400 (60:20:20)	AUC (min*ng/ml) C_{max} (ng/ml) T_{max} (hr) $t_{1/2}$ (hr) 8.5 CI/F (ml/min/kg) MRT (hr)	74698 730 0.25 8.5 13.4 7.4		
25% dispersion of compound (1-1) in PVP	AUC (min*ng/ml) C_{max} (ng/ml) T_{max} (hr) $t_{1/2}$ (hr) 8.5 CI/F (ml/min/kg) MRT (hr)		39920 77.9 1 13.8 75.2 18.0	18
25% dispersion of compound (1-1) in HPMCAS-MG	AUC (min*ng/ml) C_{max} (ng/ml) T_{max} (hr) $t_{1/2}$ (hr) 8.5 CI/F (ml/min/kg) MRT (hr)		35306 48.3 0.5 11.0 85.0 17.1	16
50% dispersion of compound (1-1) in HPMCAS-MG	AUC (min*ng/ml) C_{max} (ng/ml) T_{max} (hr) $t_{1/2}$ (hr) 8.5 CI/F (ml/min/kg) MRT (hr)		40238 67.0 2 9.5 74.6 12.8	18

[00210] Example 5. Preparation of spray dried dispersions.

10 **[00211]** Spray dried dispersions of compound (1-1) were prepared using five selected polymers: HPMCAS-MG (Shin Etsu Chemical Co., Ltd.), HPMCP-HP55 (Shin Etsu Chemical Co., Ltd.), PVP (ISP, a division of Ashland, Inc.), PVP-VA (BASF Corp.), and Eudragit L100-55 (Evonik Industries AG). All spray dried solutions were prepared at 25% and 50% by weight with each polymer. All solutions were prepared in acetone, with the exception of the PVP solutions, which were prepared in 15 ethanol. For each solution, 1.0 g of solids (polymer and compound (1-1)) were prepared in 10 g of

solvent. The solutions were spray dried using a Büchi B-290, PE-024 spray dryer with a 1.5 mm nozzle and a Büchi B-295, P-002 condenser. The spray dryer nozzle pressure was set to 80 psi, the target outlet temperature was set to 40 °C, the chiller temperature was set to -20 °C, the pump speed was set to 100%, and the aspirator setting was 100%. After spray drying, the solid dispersions were
5 collected and dried overnight in a low temperature convection oven to remove residual solvents.

[00213] Example 6: Stability with humidity and temperature.

[00214] Table 6

Test	Procedure	Acceptance Criteria	T=O (Initial)	(storage at 40°C/75%RH)	T-1 month (storage at 40°C/75%RH)	T-2 month (storage at 40°C/75%RH)	T= 3 month (storage at 40°C/75%RH)
Appearance	AM-0002	White to off-white powder	Test Date/Ref: 06Aug2012/02-41-2	Test Date/Ref: 24Sep2012/02-41-59	Test Date/Ref: 24Oct2012/02-37-106	Test Date/Ref: 17Dec2012/02-37-119	Test Date/Ref: 17Dec2012/02-37-119
Potency (HPLC)	AM-0028	45.0 ± 55.0 wt%	Test Date/Ref: 25Jul2012/02-37-21	Test Date/Ref: 25Sep2012/02-41H10	Test Date/Ref: 24Oct2012/02-37-105	Test Date/Ref: 29Nov2012/02-34-107	Test Date/Ref: 29Nov2012/02-34-107
Individual Related Substances (HPLC)	AM-0029	Report results	Test Date/Ref: 25Jul2012/02-34-49	Test Date/Ref: 26Sep2012/02-41-64	Test Date/Ref: 24Oct2012/02-37-105	Test Date/Ref: 29Nov2012/02-34-107	Test Date/Ref: 29Nov2012/02-34-107
Total Related Substances (HPLC)	AM-0029	Report results	Test Date/Ref: 25Jul2012/02-34-49	Test Date/Ref: 26Sep2012/02-41-64	Test Date/Ref: 24Oct2012/02-37-105	Test Date/Ref: 29Nov2012/02-34-107	Test Date/Ref: 29Nov2012/02-34-107
Water Content (KF)	AM-0030 USP <921>	Report results (wt%)	No reportable related substances	No reportable related substances	0.12%	0.16%	0.16%
X-Ray Powder Diffraction (XRPD)	USP <941>	Consistent with an amorphous form	Test Date/Ref: 02Aug2012/02-41-1	Test Date/Ref: 27Sep2012/02-37-99	Test Date/Ref: 25Oct2012/02-37-110	Test Date/Ref: 29Nov2012/02-37-116	Test Date/Ref: 29Nov2012/02-37-116
Modulated Differential Scanning Calorimetry (mDSC)	USP <891> (n = 2 replicates)	Report individual and average glass transition temperatures (T _g , °C)	Test Date/Ref: 24Jul2012/02-24-131	Test Date/Ref: 01Oct2012/02-41-73	Test Date/Ref: 24Oct2012/02-37-107	Test Date/Ref: 17Dec2012/02-37-120	Test Date/Ref: 17Dec2012/02-37-120
		See Figure 9	Consistent with an amorphous form	Consistent with an amorphous form See Figure 10	Consistent with an amorphous form See Figure 11	Consistent with an amorphous form See Figure 12	Consistent with an amorphous form See Figure 12
			Test Date/Ref: 24Jul2012/02-24-130	Test Date/Ref: 26Sep2012/02-37-98	Test Date/Ref: 24Oct2012/02-37-108	Test Date/Ref: 17Dec2012/02-37-121	Test Date/Ref: 17Dec2012/02-37-121
			Replicate 1 = 134.30°C, Replicate 2 = 134.23°C, Replicate 3 = 135.28°C, Average = 134.60°C	Replicate 1 = 134.65°C, Replicate 2 = 134.43°C, Replicate 3 = 134.54°C, Average = 134.93°C	Replicate 1 = 135.35°C, Replicate 2 = 137.16°C, Average = 135.14°C	Replicate 1 = 134.36°C, Replicate 2 = 135.76°C, Average = 135.00°C	Replicate 1 = 134.36°C, Replicate 2 = 135.76°C, Average = 135.00°C

[00215] Spray dried dispersions of compound (1-1) in HPMCAS-MG were assessed for stability by exposure to moisture at elevated 5 temperature. The glass transition temperature (T_g) as a function of relative humidity was determined at 75% relative humidity, 40 °C for 1, 2 and 3 months. The spray dried dispersion was stored in an LDPE bag inside a HDPE bottle to simulate bulk product packaging. The results are summarized in Table 6. At time zero, the T_g was 134 °C, at 1 month the T_g was 134 °C, at 2 months the T_g was 135 °C and at 3 months the T_g was 134 °C and only a single inflection point was observed for each measurement. X-ray diffraction patterns were also obtained for each sample. Figure 9 illustrates a powder X-ray diffraction profile of solid dispersions of compound (1-1) in HPMCAS-MG at 10 time zero of a stability test. Figures 10, 11 and 12 illustrate powder X-ray diffraction profiles of solid dispersions of compound (1-1) in

[00216] It will be appreciated by those skilled in the art that changes could be made to the exemplary embodiments shown and described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the exemplary 5 embodiments shown and described, but it is intended to cover modifications within the spirit and scope of the present invention as defined by the claims. For example, specific features of the exemplary embodiments may or may not be part of the claimed invention and features of the disclosed embodiments may be combined. Unless specifically set forth herein, the terms "a", "an" and "the" are not limited to one element but instead should be read as meaning "at least one".

[00217] It is to be understood that at least some of the figures and descriptions of the invention 10 have been simplified to focus on elements that are relevant for a clear understanding of the invention, while eliminating, for purposes of clarity, other elements that those of ordinary skill in the art will appreciate may also comprise a portion of the invention. However, because such elements are well known in the art, and because they do not necessarily facilitate a better understanding of the 15 invention, a description of such elements is not provided herein.


[00218] Further, to the extent that the method does not rely on the particular order of steps set forth herein, the particular order of the steps should not be construed as limitation on the claims. The claims directed to the method of the present invention should not be limited to the performance 20 of their steps in the order written, and one skilled in the art can readily appreciate that the steps may be varied and still remain within the spirit and scope of the present invention.

CLAIMS

I/we claim:

1. A method of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer in a mammal comprising the step of:

5 administering to a patient a pharmaceutical acceptable amount of a compound being a thienotriazolodiazepine compound of the Formula (1)



wherein R¹ is alkyl having a carbon number of 1-4, R² is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, R³ is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; —NR⁵—(CH₂)_m—R⁶ wherein R⁵ is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and R⁶ is phenyl or pyridyl optionally substituted by a halogen atom; or —NR⁷—CO—(CH₂)_n—R⁸ wherein R⁷ is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and R⁸ is phenyl or pyridyl optionally substituted by a halogen atom, and R⁴ is —(CH₂)_a—CO—NH—R⁹ wherein a is an integer of 1-4, and R⁹ is alkyl having a carbon number of 1-4; hydroxyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group or —(CH₂)_b—COOR₁₀ wherein b is an integer of 1-4, and R¹⁰ is alkyl having a carbon number of 1-4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof.

20

2. The method according to claim 1, wherein the thienotriazolodiazepine compound represented by Formula (1) is selected from the group consisting of: (i) (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo-[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof, (ii) methyl (S)-{4-(3'-cyanobiphenyl-4-yl)-2,3,9-

trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl}acetate, (iii) methyl (S)-{2,3,9-trimethyl-4-(4-phenylaminophenyl)-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl}acetate; and (iv) methyl (S)-{2,3,9-trimethyl-4-[4-(3-phenylpropionylamino)phenyl]-6H-thieno[3,2-f-][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl}acetate.

5

3. The method according to claim 2, wherein the thienotriazolodiazepine compound represented by Formula (1) is (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,-4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide dihydrate.

10 4. The method according to claim 2, wherein the thienotriazolodiazepine compound represented by Formula (1) is (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,-4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide.

15 5. The method according to claim any one of claims 1-4, wherein the thienotriazolodiazepine compound is formed as a solid dispersion.

6. The method according to claim 5, wherein the solid dispersion exhibits a single glass transition temperature (Tg) inflection point ranging from about 130 °C to about 140 °C.

20 7. The method according to claim 5, wherein the solid dispersion exhibits a single glass transition temperature (Tg) inflection point ranging from about 175 °C to about 185 °C.

25 8. The method according to claim 5, wherein the solid dispersion comprises an amorphous thienotriazolodiazepine compound of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,-4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide dihydrate and a pharmaceutically acceptable salt thereof or a hydrate thereof; and a pharmaceutically acceptable polymer.

30 9. The method according to claim 8, wherein the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,-4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide dihydrate.

10. The method according to claim 9, wherein the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline thienotriazolodiazepine compound of Formula (1).

5

11. The method according to claim 10, wherein the solid dispersion is obtained by spray drying.

12. The method according to claim 11, wherein the solid dispersion comprises an amorphous thienotriazolodiazepine compound of the Formula (1) and a pharmaceutically acceptable salt thereof or a hydrate thereof; and a pharmaceutically acceptable polymer.

10

13. The solid dispersion according to claim 12, wherein the pharmaceutically acceptable polymer is PVP.

15

14. The solid dispersion according to claim 13, wherein the solid dispersion has a thienotriazolodiazepine compound to PVP weight ratio of 1:3 to 1:1.

20

15. The method according to claim 12, wherein the pharmaceutically acceptable polymer is hydroxypropylmethylcellulose acetate succinate (HPMCAS).

25

16. The method according to claim 15, wherein the solid dispersion has a thienotriazolodiazepine compound to HPMCAS weight ratio of 1:3 to 1:1.

25

17. The method according to any one of claims 1-16, wherein the medulloblastoma is classic medulloblastoma, desmoplastic nodular medulloblastoma, large-cell medulloblastoma, medulloblastoma with neuroblastic or neuronal differentiation, medulloblastoma with glial differentiation, medullomyoblastoma, or melanotic medulloblastoma.

30

18. The method according to any one of claims 1-16, wherein the medulloblastoma is Wnt medulloblastoma, Shh medulloblastoma, Group 3 medulloblastoma or Group 4 medulloblastoma.

19. The method according to claim 18, wherein the Wnt medulloblastoma is Wnt α medulloblastoma or Wnt β medulloblastoma.

20. The method according to claim 18, wherein the Shh medulloblastoma is Shh α medulloblastoma, Shh β medulloblastoma, or Shh γ medulloblastoma.

5 21. The method according to any one of claims 1-16, wherein the ALK + non-small cell lung cancer is characterized by tumor cells having greater than about 10% ALK gene activity.

22. The method according to any one of claims 1-16, wherein the ALK + non-small cell lung cancer is characterized by tumor cells having greater than about 15% ALK gene activity.

10 23. The method according to any one of claims 21 and 22, wherein the ALK + non-small cell lung cancer comprises tumor cells having an EML4 gene fused to an ALK gene.

24. The method according to any one of claims 21 and 22, wherein ALK + non-small cell lung cancer comprises tumor cells having a KIFSB gene, TFG gene, or KLC1 gene fused to an ALK gene.

15 25. The method according to any one of claims 1-16, wherein the resistant non-Hodgkin lymphoma is a B-cell non-Hodgkin lymphoma or a T-cell non-Hodgkin lymphoma.

20 26. The method according to claim 25, wherein the resistant non-Hodgkin lymphoma is selected from the group consisting of Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma.

25 27. The method according to claim 25, wherein the resistant non-Hodgkin lymphoma is selected from the list consisting of mycosis fungoides, anaplastic large cell lymphomas, and precursor T-lymphoblastic lymphoma.

30 28. The method according to claim 25, wherein the resistant non-Hodgkin lymphoma is diffuse large B-cell lymphoma or mantle cell lymphoma.

29. The method according to any one of claims 25-28, further comprising administering a second agent, wherein the second agent is selected from the group consisting of: an mTOR inhibitor, a BTK inhibitor, an HDAC inhibitor, an anti-CD20 monoclonal antibody, a DNA methyltransferase inhibitor, an immunomodulator, or a combination thereof.

1/17




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D

3/17




FIG. 1E




FIG. 1F

4/17




FIG. 1G




FIG. 1H

5/17




FIG. 1I




FIG. 1J

6/17




FIG. 2A




FIG. 2B

7/17




FIG. 2C




FIG. 3

9/17




FIG. 4A




FIG. 4B

10/17




FIG. 4C

11/17

PLOT OF GLASS TRANSITION TEMPERATURE (T_g) VERSUS
RELATIVE HUMIDITY (RH) FOR SOLID DISPERSIONS OF COMPOUND (1-1)




FIG. 5

MODIFIED DIFFERENTIAL SCANNING CALORIMETRY TRACES
FOR 25% FORMULA (1-1)/PVP SOLID DESPERSION OF
COMPOUND (1-1) EQUILIBRATED UNDER 75% RELATIVE HUMIDITY




FIG. 6




FIG. 7A





FIG. 7B



14/17

PXRD RESULTS FOR T = 0 SAMPLE (LNR O2-24-131)




FIG. 9

15/17

PXRD RESULTS FOR 1 MONTH STABILITY SAMPLE (LNR 0241-73)




FIG. 10

16/17

PXRD RESULTS FOR 2 MONTH STABILITY SAMPLE (LNR 02-37-107)





FIG. 11

17/17

PXRD RESULTS FOR 3 MONTH STABILITY SAMPLE (LNR 02-37-120)



SUBSTITUTE SHEET (RULE 26)

FIG. 12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2015/028798

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 31/5517 (2015.01)

CPC - A61K 31/5517 (2015.05)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - A61K 31/55, 31/551, 31/5517; C07D 495/14 (2015.01)

CPC - A61K 31/55, 31/5517; C07D 471/04, 487/04 (2015.05) (keyword delimited)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC - 514/219, 220; 540/560 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatBase, Google Patents, Google Scholar.

Search terms used: THIENOTRIAZOLODIAZEPINE treat non-hodgkin lymphoma lung cancer medulloblastoma

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2013/0261109 A1 (MITSUBISHI TANABE PHARMA CORPORATION) 03 October 2013 (03.10.2013) entire document	1-3
Y	US 2014/0107107 A1 (ONCOETHIX SA) 17 April 2014 (17.04.2014) entire document	4-16
		4-16

 Further documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 June 2015

Date of mailing of the international search report

13 JUL 2015

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-8300

Authorized officer

Blaine Copenheaver

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2015/028798

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: 17-29
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.